Skip to Content

Apostolia M. Tsimberidou, M.D., Ph.D.

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Associate Member, University of Texas Health Science Center at Houston Graduate School of Biomedical Sciences, Houston, TX

Research Interests

  •  Phase I Clinical Trials
  • Target therapies
  • Cancer Molecular Biology

Click here for the most up-to-date list of Dr. Tsimberidou's publications.

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd.
Unit Number: 0455
Houston, TX 77030
Phone: (713) 792-4259
Fax: (713) 794-3249
Email: atsimber@mdanderson.org

Education & Training

Degree-Granting Education

2001 Kapodistrian University of Athens, Athens, Greece, PHD, Multidrug resistance in acute myeloid leukemia
1991 Aristotelian University of Thessaloniki, Thessaloniki, Greece, MD, Medicine

Postgraduate Training

9/2000-8/2001 Postdoctoral Research Fellow, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, Dr. Keating
9/1998-8/2000 Postdoctoral Research Fellow, Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, Dr. Cabanillas
3/1995-9/1998 Fellow in Hematology, The University of Athens, First Department of Internal Medicine, Athens, Greece, Dr. Loukopoulos
9/1993-2/1995 Residency, Internal Medicine, Theagenion Cancer Hospital, Thessaloniki, Greece, Dr. Bishiniotis
2/1992-9/1993 Internship/Residency, Internal Medicine, G. Papanicolaou Hospital, Thessaloniki, Greece, Dr. Paraskeuopoulos

Board Certifications

3/2006 ECFMG
6/1999 Board of Hematology, Athens, Greece, Valid for European Union Countries

Experience/Service

Academic Appointments

Assistant Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2007-8/2010

Professional Memberships

Cancer Network Research Workgroup, MD Anderson Cancer Center
Member, 5/2014-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Hong DS, Hui D, Bruera E, Janku F, Naing A, Falchook G, Piha-Paul SA, Wheler JJ, Fu S, Tsimberidou AM, Stecher M, Mohanty P, Simard J, Kurzrock R. A Novel, First-In-Class True Human Antibody Targeting Interleukin 1 Alpha in Refractory Cancers. Lancet Oncol. In Press.
2. Piha-Paul SA, Wheler J, Fu S, Levenback C, Lu K, Falchook G, Naing A, Hong D, Tsimberidou AM, Kurzrock R. Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the MTOR inhibitor temsirolimus. Ann Oncol. In Press.
3. Corrales-Medina FF, Herzog C, Hess K, Egas-Bejar D, Hong DS, Falchook G, Anderson P, Nunez C, Huh WW, Naing A, Tsimberidou AM, Wheler JJ, Piha Paul S, Janku F, Kleinerman ES, Kurzrock R, Subbiah V. Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: The University of Texas MD Anderson Cancer Center experience. Oncoscience. In Press.
4. Falchook G, Naing A, Wheler JJ, Tsimberidou AM, Zinner RG, Hong DS, Piha-Paul SA, Filip J, Hess KR, Bastida CC, Kurzrock R. Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer. Oncoscience. In Press.
5. Hong DS, Garrido-Laguna I, Falchook GS, Naing A, Wheler J, Fu S, Moulder S, Piha-Paul S, Tsimberidou AM, Hinojosa C, Culotta KS, Ekmekcioglu S, Wen S, Camacho LH, Ivy P, Kurzrock R. Dual inhibition of the VEGF pathway: a phase 1 trail evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors. Cancer. In Press.
6. Said RH, Ye Y, Falchook G, Janku F, Naing A, Zinner RG, Blumenschein G, Fu S, Hong DS, Piha-Paul SA, Wheler JJ, Kurzrock R, Palmer GA, Aldape K, Hess KR, Tsimberidou AM. Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials. Oncotarget. In Press.
7. Hong DS, Garrido-Laguna I, Ekmekcioglu S, Falchook GS, Naing A, Wheler JJ, Fu S, Moulder SL, Piha-Paul S, Tsimberidou AM, Wen Y, Culotta KS, Anderes K, Davis DW, Liu W, George GC, Camacho LH, Percy Ivy S, Kurzrock R. Dual inhibition of the vascular endothelial growth factor pathway: A phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors. Cancer 120(14):2164-73, 7/2014. e-Pub 4/2014. PMID: 24752867.
8. Tsimberidou AM, Wen S, Hong DS, Wheler JJ, Falchook GS, Fu S, Piha-Paul SA, Naing A, Janku F, Aldape KD, Ye Y, Kurzrock R, Berry DA. Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses. Clin Cancer Res. e-Pub 7/2014. PMID: 24987059.
9. Said R, Ye Y, Hong DS, Janku F, Fu S, Naing A, Wheler JJ, Kurzrock R, Thomas C, Palmer GA, Hess KR, Aldape K, Tsimberidou AM. Characteristics and survival of patients with advanced cancer and p53 mutations. Oncotarget 5(11):3871-9, 6/2014. PMID: 25003695.
10. Fu S, Hou MM, Wheler J, Hong D, Naing A, Tsimberidou AM, Janku F, Zinner R, Piha-Paul S, Falchook G, Kuo MT, Kurzrock R. Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies. Invest New Drugs 32(3):465-72, 6/2014. e-Pub 12/2013. PMID: 24306314.
11. Hong DS, Henary H, Falchook GS, Naing A, Fu S, Moulder S, Wheler JJ, Tsimberidou AM, Durand JB, Khan R, Yang P, Johansen M, Newman RA, Kurzrock R. First-in-human study of pbi-05204, an oleander-derived inhibitor of Akt, FGF-2, NF-kβ and p70S6K, in patients with advanced solid tumors. Invest New Drugs. e-Pub 6/2014. PMID: 24919855.
12. Wheler JJ, Moulder SL, Naing A, Janku F, Piha-Paul SA, Falchook GS, Zinner R, Tsimberidou AM, Fu S, Hong DS, Atkins JT, Yelensky R, Stephens PJ, Kurzrock R. Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway. Oncotarget 5(10):3029-38, 5/2014. PMID: 24912489.
13. Janku F, Kaseb AO, Tsimberidou AM, Wolff RA, Kurzrock R. Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular Carcinoma using targeted next generation sequencing. Oncotarget 5(10):3012-22, 5/2014. PMID: 24931142.
14. Rolfo C, Fanale D, Hong DS, Tsimberidou AM, Piha-Paul SA, Pauwels P, Van Meerbeeck JP, Caruso S, Bazan V, Cicero G, Russo A, Giovannetti E. Impact of microRNAs in resistance to chemotherapy and novel targeted agents in non-small cell lung cancer. Curr Pharm Biotechnol. e-Pub 5/2014. PMID: 24846062.
15. Hong DS, Hui D, Bruera E, Janku F, Naing A, Falchook GS, Piha-Paul S, Wheler JJ, Fu S, Tsimberidou AM, Stecher M, Mohanty P, Simard J, Kurzrock R. MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. Lancet Oncol 15(6):656-66, 5/2014. e-Pub 4/2014. PMID: 24746841.
16. Hou MM, Liu X, Wheler J, Naing A, Hong D, Bodurka D, Schmeler K, Tsimberidou AM, Janku F, Zinner R, Piha-Paul S, Hu CY, Lu K, Kurzrock R, Fu S. Outcomes of patients with metastatic cervical cancer in a phase I clinical trials program. Anticancer Res 34(5):2349-55, 5/2014. PMID: 24778042.
17. Wheler JJ, Parker BA, Lee JJ, Atkins JT, Janku F, Tsimberidou AM, Zinner R, Subbiah V, Fu S, Schwab R, Moulder S, Valero V, Schwaederle M, Yelensky R, Miller VA, Stephens MP, Meric-Bernstam F, Kurzrock R. Unique molecular signatures as a hallmark of patients with metastatic breast cancer: Implications for current treatment paradigms. Oncotarget 5(9):2349-54, 5/2014. e-Pub 5/2014. PMID: 24811890.
18. Tsimberidou AM, Keating MJ, Jabbour EJ, Ravandi-Kashani F, O'Brien S, Estey E, Bekele N, Plunkett WK, Kantarjian H, Borthakur G. A phase I study of fludarabine, cytarabine, and oxaliplatin in patients with relapsed or refractory acute myeloid leukemia. Clin Lymphoma Myeloma Leuk, 2/2014.
19. Tsimberidou AM, Adamopoulos AM, Ye Y, Piha-Paul S, Janku F, Fu S, Hong D, Falchook GS, Naing A, Wheler J, Fortier A, Kurzrock R, Hess KR. Phase I clinical trial of bendamustine and bevacizumab for patients with advanced cancer. JNCCN 12(2):194-203, 2/2014. PMID: 24586081.
20. Janku F, Hong DS, Fu S, Piha-Paul SA, Naing A, Falchook GS, Tsimberidou AM, Stepanek VM, Moulder SL, Lee JJ, Luthra R, Zinner RG, Broaddus RR, Wheler JJ, Kurzrock R. Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. Cell Rep. e-Pub 1/2014. PMID: 24440717.
21. Wheler JJ, Janku F, Falchook GS, Jackson TL, Fu S, Naing A, Tsimberidou AM, Moulder SL, Hong DS, Yang H, Piha-Paul SA, Atkins JT, Garcia-Manero G, Kurzrock R. Phase I study of Anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers. Cancer Chemother Pharmacol. e-Pub 1/2014. PMID: 24435060.
22. Said R, Banchs J, Wheler J, Hess KR, Falchook G, Fu S, Naing A, Hong D, Piha-Paul S, Ye Y, Yeh E, Wolff RA, Tsimberidou AM. The prognostic significance of left ventricular ejection fraction in patients with advanced cancer treated in phase I clinical trials. Ann Oncol 25(1):276-82, 1/2014. PMID: 24356639.
23. Jardim DL, Wheler JJ, Hess K, Tsimberidou AM, Zinner R, Janku F, Subbiah V, Naing A, Piha-Paul SA, Westin SN, Roy-Chowdhuri S, Meric-Bernstam F, Hong DS. FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors. PLoS One 9(2):e89388, 2014. e-Pub 2/2014. PMCID: PMC3929689.
24. Veasey-Rodrigues H, Parsons HA, Janku F, Naing A, Wheler JJ, Tsimberidou AM, Kurzrock R. A pilot study of temsirolimus and body composition. J Cachexia Sarcopenia Muscle 4(4):259-65, 12/2013. e-Pub 7/2013. PMCID: PMC3830004.
25. Tang C, Jardim DLF, Falchook GS, Hess K, Fu S, Wheler JJ, Zinner FG, Naing A, Tsimberidou AM, Galgiato DDM, Westin SN, Meric-Bernstam F, Kurzrock R, Hong DS. MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors. Oncoscience, 12/2013.
26. Ganesan P, Piha-Paul S, Naing A, Falchook G, Wheler J, Janku F, Zinner R, Laday S, Kies M, Tsimberidou AM. Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer. Invest New Drugs 31(6):1505-13, 12/2013. e-Pub 8/2013. PMID: 23982248.
27. Wheler JJ, Naing A, Stepanek V, Falchook GS, F S, Garrido-Laguna I, Tsimberidou AM, Piha-Paul SA, Moulder S, Lee JJ, Luthra R, Hong D, Kurzrock R. PIK3CA mutations in advanced cancers: characteristics and outcomes. Oncotarget 3(12):1566-75, 12/2013.
28. Ganesan P, Janku F, Naing A, Hong DS, Tsimberidou AM, Falchook GS, Wheler JJ, Piha-Paul SA, Fu S, Stepanek VM, Lee JJ, Luthra R, Overman MJ, Kopetz ES, Wolff RA, Kurzrock R. Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations. Mol Cancer Ther 12(12):2857-63, 12/2013. e-Pub 10/2013. PMID: 24092809.
29. Garcia SS, Atkins JT, Falchook GS, Tsimberidou AM, Hong DS, Trivedi MV, Kurzrock R. Transient severe hyperbilirubinemia after hepatic arterial infusion of oxaliplatin in patients with liver metastases. Cancer Chemother Pharmacol 72(6):1265-71, 12/2013. e-Pub 10/2013. PMID: 24101145.
30. Veasey Rodrigues H, Baracos VE, Wheler JJ, Parsons HA, Hong DS, Naing A, Fu S, Falchoock G, Tsimberidou AM, Piha-Paul S, Chisholm G, Kurzrock R. Body composition and survival in the early clinical trials setting. Eur J Cancer 49(15):3068-75, 10/2013. e-Pub 7/2013. PMID: 23867127.
31. Wheler JJ, Tsimberidou AM, Falchook GS, Zinner RG, Hong DS, Fok JY, Fu S, Piha-Paul SA, Naing A, Kurzrock R. Combining erlotinib and cetuximab is associated with activity in patients with non small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutations. Mol Cancer Ther 12(10):2167-75, 10/2013. e-Pub 8/2013. PMID: 23963360.
32. Tsimberidou AM, Vaklavas C, Fu S, Wen S, Lim JA, Hong D, Wheler J, Naing A, Uehara C, Wallace M, Kurzrock R. Hepatic arterial infusion therapy in advanced cancer and liver-predominant disease: the MD Anderson Experience. Hepatogastroenterology 60(127):1611-23, 10/2013. PMID: 24634931.
33. Tsimberidou AM, Wierda WG, Wen S, Plunkett W, O'Brien S, Kipps TJ, Jones JA, Badoux X, Kantarjian H, Keating MJ, Chronic Lymphocytic Leukemia Research Consortium. Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or richter syndrome. Clin Lymphoma Myeloma Leuk 13(5):568-74, 10/2013. e-Pub 6/2013. PMID: 23810245.
34. Hong D, Said R, Falchook G, Naing A, Moulder S, Tsimberidou AM, Galluppi G, Dakappagari N, Storgard C, Kurzrock R, Rosen LS. Phase I study of BIIB028, a selective heat shock protein 90 inhibitor, in patients with refractory metastatic or locally advanced solid tumors. Clin Cancer Res 19(17):4824-31, 9/2013. e-Pub 7/2013. PMCID: PMC3935614.
35. Henary H, Hong DS, Falchook GS, Tsimberidou AM, George GC, Wen S, Wheler J, Fu S, Naing A, Piha-Paul S, Janku F, Kim KB, Hwu P, Kurzrock R. Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes. Ann Oncol 24(8):2158-65, 8/2013. e-Pub 4/2013. PMID: 23576709.
36. Féliz LR, Tsimberidou AM. Anti-vascular endothelial growth factor therapy in the era of personalized medicine. Cancer Chemother Pharmacol 72(1):1-12, 7/2013. e-Pub 3/2013. PMID: 23463481.
37. Ganesan P, Piha-Paul S, Naing A, Falchook G, Wheler J, Fu S, Hong DS, Kurzrock R, Janku F, Laday S, Bedikian AY, Kies M, Wolff RA, Tsimberidou AM. Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer. Invest New Drugs. e-Pub 6/2013. PMID: 23756764.
38. Wheler J, Hong D, Swisher SG, Falchook G, Tsimberidou AM, Helgason T, Naing A, Stephen B, Janku F, Stephens PJ, Yelensky R, Kurzrock R. Thymoma patients treated in a phase I clinic at MD Anderson Cancer Center: responses to mTOR inhibitors and molecular analyses. Oncotarget 4(6):890-8, 6/2013. PMCID: PMC3757246.
39. Said R, Hong DS, Warneke CL, Lee JJ, Wheler JJ, Janku F, Naing A, Falchook GS, Fu S, Piha-Paul S, Tsimberidou AM, Kurzrock R. P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy. Oncotarget 4(5):705-14, 5/2013. e-Pub 5/2013. PMCID: PMC3742831.
40. Wheler J, Falchook G, Tsimberidou AM, Hong D, Naing A, Piha-Paul S, Chen SS, Heymach J, Fu S, Stephen B, Fok JY, Janku F, Kurzrock R. Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population. Oncotarget 4(5):772-84, 5/2013. PMCID: PMC3742837.
41. Tsimberidou AM, Ye Y, Wheler J, Naing A, Hong D, Nwosu U, Hess KR, Wolff RA. A phase I study of hepatic arterial infusion of nab-paclitaxel in combination with intravenous gemcitabine and bevacizumab for patients with advanced cancers and predominant liver metastases. Cancer Chemother Pharmacol 71(4):955-63, 4/2013. e-Pub 2/2013. PMCID: PMC3977741.
42. Wheler JJ, Falchook GS, Tsimberidou AM, Hong DS, Naing A, Piha-Paul SA, Chen SS, Fu S, Stephen B, Fok JY, Janku F, Kurzrock R. Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: Implications for therapy. Ann Oncol 24(3):838-42, 3/2013. e-Pub 11/2012. PMID: 23139256.
43. Holsinger FC, Piha-Paul SA, Janku F, Hong DS, Atkins JT, Tsimberidou AM, Kurzrock R. Biomarker-directed therapy of squamous carcinomas of the head and neck: Targeting PI3K/PTEN/mTOR pathway. J Clin Oncol 31(9):e137-40, 3/2013. e-Pub 1/2013. PMID: 23358976.
44. Tsimberidou AM, Leick MB, Lim J, Fu S, Wheler J, Piha-Paul SA, Hong D, Falchook GS, Naing A, Subbiah IM, Fortier A, Avritscher R, Kurzrock R. Dose-finding study of hepatic arterial infusion of oxaliplatin-based treatment in patients with advanced solid tumors metastatic to the liver. Cancer Chemother Pharmacol 71(2):389-97, 2/2013. e-Pub 11/2012. PMID: 23143207.
45. Gupta V, Richards S, Rowe J, Acute Leukemia Stem Cell Transplantation Trialists' Collaborative Group [Tsimberidou A]. Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysis. Blood 121(2):339-50, 1/2013. e-Pub 11/2012. PMID: 23165481.
46. Falchook GS, Naing A, Hong DS, Zinner R, Fu S, Piha-Paul SA, Tsimberidou AM, Morgan-Linnell SK, Jiang Y, Bastida C, Wheler JJ, Kurzrock R. Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer. Oncotarget 4(1):118-27, 1/2013. PMCID: PMC3702212.
47. Janku F, Wheler JJ, Naing A, Falchook GS, Hong DS, Stepanek VM, Fu S, Piha-Paul SA, Lee JJ, Luthra R, Tsimberidou AM, Kurzrock R. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early phase clinical trials. Cancer Res 73(1):276-84, 1/2013. e-Pub 10/2012. PMCID: PMC3537862.
48. Subbiah IM, Subbiah V, Tsimberidou AM, Naing A, Kaseb AO, Javle M, Fu S, Hong DS, Piha-Paul S, Wheler JJ, Hess KR, Janku F, Falchook GS, Wolff RA, Kurzrock R. Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials. Oncotarget 4(1):153-62, 1/2013. e-Pub 1/2013. PMCID: PMC3702215.
49. Shim S, Stemke-Hale K, Tsimberidou AM, Noshari J, Anderson TE, Gascoyne PR. Antibody-independent isolation of circulating tumor cells by continuous-flow dielectrophoresis. Biomicrofluidics 7(1):12, 2013. e-Pub 1/2013. PMCID: PMC3562332.
50. Fu S, McQuinn L, Naing A, Wheler JJ, Janku F, Falchook GS, Piha-Paul SA, Tu D, Howard A, Tsimberidou AM, Zinner R, Hong DS, Kurzrock R. Barriers to study enrollment in patients with advanced cancer referred to a phase I clinical trials unit. Oncologist 18(12):1315-20, 2013. e-Pub 10/2013. PMCID: PMC3868426.
51. Vinas LR, Tsimberidou AM. Safety of bevacizumab. Journal of Symptoms and Signs 2(3):127-136, 2013.
52. Hong DS, Patel JC, Wheler J, Naing A, Garrido-Laguna I, Falchook G, Fu S, Tsimberidou AM, Kopetz S, Win S, Kurzrock R. Outcomes in 144 patients with colorectal cancer treated in a phase I clinic: the MD Anderson Cancer Center experience. Clin Colorectal Cancer 11(4):297-303, 12/2012. e-Pub 4/2012. PMID: 22537607.
53. Naing A, Veasey-Rodrigues H, Hong DS, Fu S, Falchook GS, Wheler JJ, Tsimberidou AM, Wen S, Fessahaye SN, Golden EC, Aaron J, Ewer MS, Kurzrock R. Electrocardiograms in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs. Ann Oncol 23(11):2960-3, 11/2012. e-Pub 6/2012. PMID: 22745218.
54. Fu S, Barber FD, Naing A, Wheler J, Hong D, Falchook G, Piha-Paul S, Tsimberidou A, Howard A, Kurzrock R. Advance care planning in patients with cancer referred to a phase I clinical trials program: The MD Anderson Cancer Center experience. J Clin Oncol 30(23):2891-6, 8/2012. e-Pub 7/2012. PMID: 22778314.
55. Wheler JJ, Tsimberidou AM, Hong DS, Naing A, Falchook GS, Fu S, Moulder S, Stephen B, Wen S, Kurzrock R. Risk of serious toxicity in 1,181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: The MD Anderson Cancer Center Experience. Ann Oncol 23(8):1963-7, 8/2012. e-Pub 2/2012. PMID: 22377564.
56. Tsimberidou AM, Fu S, Subbiah IM, Naing, A, Hong DS, Wen S, Fortier AH, Lim J, Kurzrock R. Intraperitoneal and intravenous chemotherapy in peritoneal carcinomatosis. Hepato-Gastroenterol 59(116):960-4, 2012 July-Aug, 7/2012. PMID: 22584909.
57. Tsimberidou AM, Fu S, Subbiah IM, Naing A, Hong DS, Wen S, Fortier AH, Lim J, Kurzrock R. Intraperitoneal and intravenous chemotherapy in peritoneal carcinomatosis. Hepatogastroenterology 59(116):960-4, 6/2012. PMID: 22580643.
58. Segler A, Tsimberidou AM. Lenalidomide in solid tumors. Cancer Chemother Pharmacol 69(6):1393-406, 6/2012. e-Pub 5/2012. PMID: 22584909.
59. Wheler J, Tsimberidou AM, Hong D, Naing A, Falchook G, Piha-Paul S, Fu S, Moulder S, Stephen B, Wen S, Kurzrock R. Survival of 1,181 patients in a phase I clinic: The MD Anderson Clinical Center for Targeted Therapy Experience. Clin Cancer Res 18(10):2922-9, 5/2012. e-Pub 3/2012. PMID: 22452943.
60. Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Garrido-Laguna I, Luthra R, Lee JJ, Lu KH, Kurzrock R. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol 30(8):777-82, 3/2012. e-Pub 1/2012. PMCID: PMC3295566.
61. Garrido-Laguna I, Janku F, Vaklavas C, Falchook GS, Fu S, Hong DS, Naing A, Tsimberidou AM, Wen S, Kurzrock R. Validation of the Royal Marsden Hospital prognostic score in patients treated in the phase I clinical trials program at the MD Anderson Cancer Center. Cancer 118(5):1422-8, 3/2012. e-Pub 8/2011. PMID: 21823111.
62. Parsons HA, Tsimberidou AM*, Pontikos M, Fu S, Hong D, Wen S, Baracos VE, Kurzrock R. Evaluation of the clinical relevance of body composition parameters in patients with cancer metastatic to the liver treated with hepatic arterial infusion chemotherapy. Nutr Cancer 64(2):206-17, 2012. PMID: 22229660.
63. Tsimberidou AM, Lewis N, Reid T, Burris H, Urban P, Tan EY, Anand S, Uehara C, Kurzrock R. Pharmacokinetics and antitumor activity of patupilone combined with midazolam or omeprazole in patients with advanced cancer. Cancer Chemother Pharmacol 68(6):1507-16, 12/2011. e-Pub 4/2011. PMID: 21499896.
64. Nabhan C, Tsimberidou AM. Therapy-related myeloid neoplasia after fludarabine and cyclophosphamide for chronic lymphocytic leukemia. Blood. e-Pub 11/2011.
65. Tsimberidou AM, Letourneau K, Fu S, Hong D, Naing A, Wheler J, Uehara C, McRae SE, Wen S, Kurzrock R. Phase I clinical trial of hepatic arterial infusion of paclitaxel in patients with advanced cancer and dominant liver involvement. Cancer Chemother Pharmacol 68(1):247-53, 7/2011. e-Pub 10/2010. PMID: 20941597.
66. Tsimberidou AM, Letourneau K, Wen S, Wheler J, Hong D, Naing A, Iskander NG, Uehara C, Kurzrock R. Phase I clinical trials in 93 patients with brain metastases: The MD Anderson Cancer Center experience. Clin Cancer Res 17(12):4110-8, 6/2011. e-Pub 3/2011. PMID: 21415223.
67. Vaklavas C, Chatzizisis YS, Tsimberidou AM. Common cardiovascular medications in cancer therapeutics. Pharmacol Ther 130(2):177-90, 5/2011. e-Pub 1/2011. PMID: 21277894.
68. Hong DS, Cabanillas ME, Wheler J, Naing A, Tsimberidou AM, Ye L, Waguespack SG, Hernandez M, El Naggar AK, Bidyasar S, Wright J, Sherman SI, Kurzrock R. Inhibition of the Ras/Raf/MEK/ERK and RET Kinase Pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies. J Clin Endocrinol Metab 96(4):997-1005, 4/2011. e-Pub 2/2011. PMCID: PMC3070247.
69. Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, Naing A, Falchook GS, Moroney JW, Piha-Paul SA, Wheler JJ, Moulder SL, Fu S, Kurzrock R. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitor. Mol Cancer Ther 10(3):558-65, 3/2011. e-Pub 1/2011. PMCID: PMC3072168.
70. Tsimberidou AM, Takimoto CH, Moulder S, Uehara C, Mita M, Mita A, Urban P, Tan E, Wang Y, Vining D, Kurzrock R. Effects of patupilone on the pharmacokinetics and pharmacodynamics of warfarin in patients with advanced malignancies: a phase I clinical trial. Mol Cancer Ther 10(1):209-17, 1/2011. PMID: 21220503.
71. Vaklavas C, Tsimberidou AM*, Wen S, Hong D, Wheler J, Ng CS, Naing A, Uehara C, Wolff RA, Kurzrock R. Phase 1 clinical trials in 83 patients with pancreatic cancer: the M. D. Anderson Cancer Center experience. Cancer 117(1):77-85, 1/2011. e-Pub 8/2010. PMID: 20737567.
72. El-Osta H, Falchook G, Tsimberidou A, Hong D, Naing A, Kim K, Wen S, Janku F, Kurzrock R. BRAF mutations in advanced cancers: clinical characteristics and outcomes. PLoS One 6(10):e25806, 2011. e-Pub 10/2011. PMCID: PMC3198456.
73. Subbiah IM, Lenihan DJ, Tsimberidou AM. Cardiovascular toxicity profiles of vascular-disrupting agents. Oncologist 16(8):1120-30, 2011. e-Pub 7/2011. PMID: 21742963.
74. Janku F, Tsimberidou AM, Wang X, Hong DS, Naing A, Gong J, Garrido-Laguna I, Parsons HA, Zinner RG, Kurzrock R. Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinic. Oncologist 16(3):327-35, 2011. e-Pub 2/2011. PMID: 21339262.
75. El-Osta H, Hong D, Wheler J, Fu S, Naing A, Falchook G, Hicks M, Wen S, Tsimberidou AM, Kurzrock R. Outcomes of research biopsies in phase I clinical trials: the MD Anderson Cancer Center Experience. Oncologist 16(9):1292-8, 2011. e-Pub 8/2011. PMID: 21859821.
76. Janku F, Lee JJ, Tsimberidou AM, Hong DS, Naing A, Falchook GS, Fu S, Luthra R, Garrido-Laguna I, Kurzrock R. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS One 6(7):e22769, 2011. e-Pub 7/2011. PMCID: PMC3146490.
77. Tsimberidou AM, Akerley W, Schabel MC, Hong DS, Uehara C, Chhabra A, Warren T, Mather GG, Evans BA, Woodland DP, Swabb EA, Kurzrock R. Phase I clinical trial of MPC-6827 (Azixa), a microtubule destabilizing agent, in patients with advanced cancer. Mol Cancer Ther 9(12):3410-9, 12/2010. PMID: 21159616.
78. Tsimberidou AM, Moulder S, Fu S, Wen S, Naing A, Bedikian AY, Daring S, Uehara C, Ng C, Wallace M, Camacho L, Kurzrock R. Phase I clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvement. Cancer Chemother Pharmacol 66(6):1087-93, 11/2010. e-Pub 3/2010. PMID: 20204368.
79. Tsimberidou AM, Fu S, Ng C, Lim JA, Wen S, Hong D, Wheler J, Bedikian AY, Eng C, Wallace M, Camacho LH, Kurzrock R. A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver. Cancer 116(17):4086, 9/2010. e-Pub 5/2010. PMID: 20564148.
80. Vaklavas C, Sotelo-Rafiq EP, Lovy J, Escobar MA, Tsimberidou AM. Progressive multifocal leukoencephalopathy in a patient without apparent immunosuppression. Virol J 7:256, 9/2010. PMCID: PMC2954859.
81. Tsimberidou AM, Keating MJ. Treatment of patients with fludarabine-refractory chronic lymphocytic leukemia: need for new treatment options. Leuk Lymph 51(7):1188-1199, 7/2010. PMID: 20545582.
82. Wheler J, Tsimberidou AM, Moulder S, Cristofanilli M, Hong D, Naing A, Pathak R, Liu S, Feng L, Kurzrock R. Clinical outcomes of patients with breast cancer in a phase I clinic: The M. D. Anderson Cancer Center Experience. Clin Breast Cancer 10(1):46-51, 2/2010. PMID: 20133258.
83. Tarrand JJ, Keating MJ, Tsimberidou AM, O'Brien S, LaSala RP, Han XY, Bueso-Ramos CE. Epstein-Barr virus latent membrane Protein 1 mRNA is expressed in a significant proportion of patients with chronic lymphocytic leukemia. Cancer 116(4):880-7, 2/2010. e-Pub 1/2010. PMID: 20052729.
84. Tsimberidou AM, Rudek MA, Hong D, Ng CS, Blair J, Goldsweig H, Kurzrock R. Phase 1 first-in-human, clinical study of S-trans, trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors. Cancer Chemother Pharmacol (Cover Sidebar) 65(2):235-41, 1/2010. e-Pub 5/2009. PMID: 19484470.
85. Vaklavas C, Lenihan D, Kurzrock R, Tsimberidou AM. Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: What are the important clinical markers to target? Oncologist 15(2):130-41, 2010. e-Pub 2/2010. PMID: 20139170.
86. Tsimberidou AM, Braiteh F, Stewart DJ, Kurzrock R. Ultimate fate of oncology drugs approved by the Food and Drug Administration without a randomized trial. J Clin Oncol (Cover Sidebar) 27(36):6243-50, 12/2009. e-Pub 10/2009. PMID: 19826112.
87. Aguilera DG, Vaklavas C, Tsimberidou AM*, Wen S, Medeiros LJ, Corey SJ. Pediatric therapy-related myelodysplastic syndrome/acute myeloid leukemia: The M. D. Anderson Cancer Center Experience. J Pediatr Hematol Oncol 31(11):803-11, 11/2009. PMID: 19801947.
88. Tsimberidou AM, Vaklavas C, Wen S, Hong D, Wheler J, Ng C, Naing A, Tse S, Busaidy N, Markman M, Sherman SI, Kurzrock R. Phase I clinical trials in 56 patients with thyroid cancer: The M. D. Anderson Cancer Center Experience. J Clin Endocrinol Metab 94(11):4423-32, 11/2009. e-Pub 10/2009. PMCID: PMC2775645.
89. Vemulapalli S, Chintala L, Tsimberidou AM*, Dhillon N, Lei X, Hong D, Kurzrock R. Clinical outcomes and factors predicting development of venous thromboembolic complications in patients with advanced refractory cancer in a phase I clinic: The M. D. Anderson Cancer Center Experience. Am J Hematol 84(7):408-13, 7/2009. e-Pub 3/2009. PMID: 19437507.
90. Wheler J, Tsimberidou AM, Hong D, Naing A, Jackson T, Liu S, Feng L, Kurzrock R. Survival of patients in a Phase 1 Clinic: the M. D. Anderson Cancer Center experience. Cancer 115(5):1091-9, 3/2009. PMID: 19165805.
91. Tsimberidou AM, Wen S, McLaughlin P, O'Brien S, Wierda WG, Lerner S, Strom S, Freireich EJ, Medeiros LJ, Kantarjian HM, Keating MJ. Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma. J Clin Oncol 27(6):904-10, 2/2009. e-Pub 12/2008. PMID: 19114699.
92. Tsimberidou AM, Camacho LH, Verstovsek S, Ng C, Hong DS, Uehara CK, Gutierrez C, Daring S, Stevens J, Komarnitsky PB, Schwartz B, Kurzrock R. A phase I clinical trial of darinaparsin in patients with refractory solid tumors. Clin Cancer Res (Cover Sidebar) 15(14):4769-76, 2009. e-Pub 7/2009. PMID: 19584162.
93. Tsimberidou AM, Tam C, Abruzzo LV, O'Brien S, Wierda WG, Lerner S, Kantarjian K, Keating MJ. Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia. Cancer 115(2):373-80, 2009. PMID: 19117034.
94. Tsimberidou AM, Keating MJ. Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma: analysis of 2028 patients. Am J Hematol (Cover Sidebar) 8(9):430-32, 2009.
95. Tsimberidou AM, Keating MJ.. Treatment of fludarabine-refractory chronic lymphocytic leukemia. Cancer 115(13):2824-36, 2009. PMID: 19402170.
96. Tsimberidou AM, Estey E, Wen S, Pierce S, Kantarjian H, Albitar M, Kurzrock R. The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes. Cancer 113(7):1605-13, 10/2008. PMID: 18683214.
97. Tsimberidou AM, Kantarjian HM, Wen S, Keating MJ, O'Brien S, Brandt M, Pierce S, Freireich EJ, Medeiros LJ, Estey E. Myeloid sarcoma is associated with superior event-free survival and overall survival compared with acute myeloid leukemia. Cancer 113(6):1370-8, 2008. PMCID: PMC2574728.
98. Tsimberidou AM, Wierda WG, Plunkett W, Kurzrock RA, O'Brien S, Wen S, Ferrajoli A, Ravandi F, Garcia-Manero G, Estrov Z, Kipps TJ, Brown JR, Fiorentino A, Lerner S, Kantarjian HM, Keating MJ.. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 26(2):196-203, 2008. PMID: 18182662.
99. Tsimberidou AM, Estey E. Relevance of clinical trials in acute myeloid leukemia. Hematol Oncol 26(3):182-3, 2008.
100. Tsimberidou AM, Wen S, O'Brien S, McLaughlin P, Wierda WG, Ferrajoli A, Faderl S, Manning J, Lerner S, Mai CV, Rodriguez AM, Hess M, Do KA, Freireich EJ, Kantarjian HM, Medeiros LJ, Keating MJ. Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M. D. Anderson Cancer Center. J Clin Oncol 25(29):4648-56, 10/2007. PMID: 17925562.
101. Tam CS, O'Brien S, Lerner S, Khouri I, Ferrajoli A, Faderl S, Browning M, Tsimberidou AM, Kantarjian H, Wierda WG. The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy. Leuk Lymphoma 48(10):1931-9, 2007.
102. Tsimberidou AM, Catovsky D, Schlette E, O'Brien S, Wierda WG, Kantarjian H, Garcia-Manero G, Wen S, Do KA, Lerner S, Keating MJ. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer 107(1):125-35, 7/2006. PMID: 16700034.
103. Ahmed B, Estey E, Manning J, David C, Keating MJ, Kantarjian H, Tsimberidou AM. Anaplastic large cell lymphoma with involvement of the pancreas presenting as panniculitis in a patient with a history of acute myeloid leukemia - case report and review of the literature. Haematologica 91(12 Suppl):ECR55, 2006. PMID: 17194661.
104. Tsimberidou AM, O'Brien S, Khouri I, Giles FJ, Kantarjian HM, Champlin R, Wen S, Do K-A, Smith SC, Lerner S, Freireich EJ, Keating MJ.. Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem cell transplantation. J Clin Oncol 24(15):2343-51, 2006. PMID: 16710033.
105. Bruzzi JF, Macapinlac HA, Tsimberidou AM, Truong MT, Keating MJ, Marom EM, Munden RF.. Detection of Richter's transformation of chronic lymphocytic leukemia by PET/CT. J Nucl Med 47(8):1267-73, 2006. PMID: 16883004.
106. Tsimberidou AM, Keating MJ, Bueso-Ramos CE, Kurzrock R. Epstein-Barr virus in patients with chronic lymphocytic leukemia: a pilot study. Leuk Lymphoma 47(5):827-36, 2006. PMID: 16753866.
107. Tsimberidou AM, Estey E, Kantarjian H, Keating MJ, Pierce S, Garcia-Manero G. Granulocyte colony stimulating factor administration associated with cerebral hemorrhage in acute promyelocytic leukemia. Leukemia 20(8):1452-3, 2006. e-Pub 5/2006. PMID: 16728980.
108. Tsimberidou AM, O'Brien S, Kantarjian HM, Koller C, Hagemeister FB, Fayad L, Lerner S, Bueso-Ramos CE, Keating MJ.. Hodgkin transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience. Cancer 107(6):1294-302, 2006. PMID: 16902984.
109. Liu Q, Fayad L, Cabanillas F, Hagemeister FB, Ayers GD, Hess M, Romaguera J, Rodriguez MA, Tsimberidou AM, Verstovsek S, Younes A, Pro B, Lee MS, Ayala A, McLaughlin P.. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at the University of Texas M. D. Anderson Cancer Center. J Clin Oncol (Cover Sidebar) 24(10):1582-9, 2006. PMID: 16575009.
110. Tsimberidou AM, Estey E. Induction mortality risk in adult acute myeloid leukemia. Leuk Lymphoma 47(7):1199-200, 2006. PMID: 16923545.
111. Garcia GM, Deavers MT, Knoblock R, Chen W, Tsimberidou AM, Manning JT, Medeiros LJ. Myeloid sarcoma involving the gynecologic tract: a report of 11 cases and review of the literature. Am J Clin Pathol 125(5):783-90, 2006.
112. Tsimberidou AM, Tirado-Gomez M, Andreef M, O'Brien S, Kantarjian H, Keating MJ, Lopez-Berestein G, Estey E.. Single-agent liposomal all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemia: An update of the University of Texas M. D. Anderson Cancer Center series. Leuk Lymphoma 47(6):1062-8, 2006. PMID: 16840198.
113. Tsimberidou AM, Giles FJ, Estey E, O'Brien S, Keating MJ, Kantarjian H. The role of gemtuzumab ozogamicin in acute leukemia therapy. Br J Haematol 132(4):398-09, 2006.
114. Giles FJ, Kantarjian HM, Cortes JE, Faderl S, Verstovsek S, Thomas D, Garcia-Manero G, Wierda W, Ferrajoli A, Kornblau S, Mattiuzzi GN, Tsimberidou AM, Albitar M, O'Brien SM, Estey E. Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes. Leukemia Res 29:649-52, 2005. PMID: 15863204.
115. Tsimberidou AM Giles FJ, Khouri I, Bueso-Ramos C, Pilat S, Thomas DA, Cortes J, Kurzrock R. Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience. Ann Oncol 16:139-45, 2005. PMID: 15598951.
116. Estey E, Koller C, Tsimberidou AM, O'Brien S, Beran M, Cortes J, Tirado-Gomez M, Lopez-Berestein G, Kantarjian H. Potential curability of newly diagnosed acute promyelocytic leukemia without use of "chemotherapy": the example of liposomal all-trans retinoic acid. Blood 105(3):1366-7, 2005. PMID: 15659618.
117. Tsimberidou AM, Giles F, Romaguera J, Duvic M, Kurzrock R. Activity of interferon-alpha and isotretinoin in patients with advanced, refractory lymphoid malignancies. Cancer 100:574-80, 2004. PMID: 14745875.
118. Tsimberidou AM, Medina J, Cortes J, Rios A, Bonnie G, Faderl S, Kantarjian H, Garcia-Manero G. Chronic myelogenous leukemia in a patient with acquired immune deficiency syndrome: complete cytogenetic response with imatinib mesylate. Report of a case and review of the literature. Leukemia Res 28:657-60, 2004. PMID: 15120945.
119. Tsimberidou AM, Estey E, Whitman GJ, Dryden MJ, Ratnam S, Pierce S, Faderl S, Giles F, Kantarjian HM, Garcia-Manero G. Extramedullary relapse in a patient with acute promyelocytic leukemia: treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies. Leukemia Res 28(9):991-4, 2004. PMID: 15234578.
120. Tsimberidou AM, Keating MJ, Giles FJ, Wierda WG, Ferrajoli A, Lerner S, Beran M, Andreeff M, Kantarjian HM, O'Brien S. Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia. Cancer 100:2583-91, 2004. PMID: 15197800.
121. Tsimberidou AM, Giles F, Duvic M, Fayad L, Kurzrock R. Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series. Cancer 100:342-9, 2004. PMID: 14716770.
122. Tsimberidou AM, Giles FJ, Duvic M, Kurzrock R. Pilot study of etanercept in patients with relapsed cutaneous T-cell lymphomas. J Am Acad Dermatol 51:200-4, 2004. PMID: 15280837.
123. Tsimberidou AM, Murray JL, O'Brien S, Wierda WG, Keating MJ. Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in Richter's syndrome. Cancer 100:2195-200, 2004. PMID: 15139064.
124. Tsimberidou AM, Colburn DE, Welch MA, Cortes JE, Verstovsek S, O'Brien SM, Albitar M, Kantarjian HM, Giles FJ. Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders. Cancer Chemother Pharmacol 52:229-34, 2003. PMID: 12783207.
125. Tsimberidou AM, Giles FJ, Kantarjian HM, Keating MJ, O'Brien SM. Anti-B4 blocked ricin post chemotherapy in patients with chronic lymphocytic leukemia-long-term follow-up of a monoclonal antibody-based approach to residual disease. Leuk Lymphoma 44:1719-25, 2003. PMID: 14692524.
126. Yazji S, Giles FJ, Tsimberidou AM, Estey EH, Kantarjian HM, O'Brien SA, Kurzrock R. Antithymocyte globulin-based therapy in patients with myelodysplastic syndromes. Leukemia 17:2101-06, 2003. PMID: 12931212.
127. Tsimberidou AM, Stavroyianni N, Viniou N, Papaioannou M, Tiniakou M, Marinakis T, Skandali A, Sakellari I, Yataganas X. Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia. Cancer 97:1721-31, 2003. PMID: 12655529.
128. Tsimberidou AM, Kantarjian HM, Cortes J, Thomas DA, Faderl S, Garcia-Manero G, Verstovsek S, Ferrajoli A, Wierda W, Alvarado Y, O'Brien SM, Albitar M, Keating MJ, Giles FJ. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. Cancer 97:1711-20, 2003. PMID: 12655528.
129. Tsimberidou A, Cortes J, Thomas D, Garcia-Manero G, Verstovsek S, Faderl S, Albitar M, Kantarjian H, Estey E, Giles FJ. Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. Leukemia Res 27:893-97, 2003. PMID: 12860008.
130. Tsimberidou AM, Medina J, Earl M, Sierra M, Shriki JE, Bueso-Ramos C, Giralt S, Beran M, Giles FJ, Garcia-Manero G. Metastatic gastric adenocarcinoma following allogeneic stem cell transplantation in a patient with acute myelogenous leukemia. Bone Marrow Transplant 31:413-14, 2003. PMID: 12634736.
131. Apostolidou E, Estey E, Cortes J, Garcia-Manero G, Faderl S, Thomas D, Tsimberidou A, Kantarjian H, Giles FJ. Mitoxantrone and prolonged infusion gemcitabine as salvage therapy in patients with acute myelogenous leukemia. Leukemia Res 27:301-4, 2003. PMID: 12531220.
132. Tsimberidou A, Estey E, Cortes J, Thomas D, Faderl S, Verstovsek S, Garcia-Manero G, Keating M, Albitar M, O'Brien S, Kantarjian H, Giles F. Mylotarg, fludarabine, cytarabine and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes. Cancer 97:1481-7, 2003.
133. Tsimberidou AM, Estey E, Cortes JE, Garcia-Manero G, Faderl S, Verstovsek S, Thomas DA, Ferrajoli A, Keating MJ, O'Brien S, Kantarjian HM, Giles FJ. Mylotarg, fludarabine, cytarabine, and cyclosporine regimen as post-remission therapy in acute myelogenous leukemia. Cancer Chemother. Pharmacol. 52:449-52, 2003. PMID: 13680159.
134. Alvarado Y, Tsimberidou AM, Cortes J, Garcia-Manero G, Giles FJ,. Mylotarg, idarubicin and ara-C combination regimen in patients with CD33-positive primary resistant or relapsed acute myeloid leukemia. Cancer Chemother Pharmacol 51(1):87-90, 2003.
135. Tsimberidou AM, Kantarjian HM, Estey E, Cortes JE, Verstovsek S, Faderl S, Thomas DA, Garcia-Manero G, Ferrajoli A, Manning JT, Keating MJ, Albitar M, O'Brien S, Giles FJ. Outcome in patients with non-leukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy. Leukemia 17:1100-3, 2003. PMID: 12764375.
136. Apostolidou E, Cortes J, Tsimberidou A, Estey E, Kantarjian H, Giles FJ. Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia. Leukemia Res 27:887-91, 2003. PMID: 12860007.
137. Alvarado Y, Tsimberidou A, Kantarjian H, Cortes J, Garcia-Manero G, Faderl S, Thomas D, Estey E, Giles FJ. Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia. Cancer Chemother Pharmacol 51:87-90, 2003. PMID: 12497211.
138. Tsimberidou AM, Waddelow T, Kantarjian HM, Albitar M, Giles FJ. Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: increase in plasma TNF alpha levels during treatment. Leukemia Res 27:375-80, 2003. PMID: 12620287.
139. Tsimberidou AM, Giles FJ. Essential thrombocythemia: moving from palliation to cure. Hematology 7:315-23, 2002. PMID: 12475736.
140. Tsimberidou AM, Paterakis G, Androutsos G, Anagnostopoulos N, Galanopoulos A, Kalmantis T, Meletis J, Rombos Y, Sagriotis A, Symeonidis A, Tiniakou M, Zoumbos N, Yataganas X. Evaluation of the clinical relevance of the expression and function of P-glycoprotein, multidrug resistance protein and lung resistance protein in patients with primary acute myelogenous leukemia. Leukemia Res 26:143-54, 2002. PMID: 11755464.
141. Tsimberidou AM, McLaughlin P, Younes A, Rodriguez MA, Hagemeister FB, Sarris A, Romaguera J, Hess M, Smith TL, Yang Y, Ayala A, Preti A, Lee MS, Cabanillas F. Fludarabine, mitoxantrone, dexamethasone compared with an alternating triple therapy regimen in patients with stage IV indolent lymphoma. Blood 100:4351-7, 2002. PMID: 12393618.
142. Cortes J, Tsimberidou AM, Alvarez R, Thomas D, Beran M, Kantarjian H, Estey E, Giles FJ. Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia. Cancer Chemother Pharmacol 50:497-500, 2002. PMID: 12451477.
143. Tsimberidou AM, O'Brien SM, Cortes JE, Faderl S, Andreeff M, Kantarjian HM, Keating MJ, Giles FJ. Phase II study of fludarabine, cytarabine, cyclophosphamide, cisplatin and GM-CSF in patients with Richter's syndrome or refractory lymphoproliferative disorders. Leuk Lymphoma 43:767-72, 2002. PMID: 12153163.
144. Tsimberidou AM, Jiang Y, Ford RJ, Lichtiger B, Lee MS, Medeiros LJ, McLaughlin P, Cabanillas F, Sarris AS.. Quantitative real-time polymerase chain reaction for detection of circulating cells with t(14;18) in volunteer blood donors and patients with follicular lymphoma. Leuk Lymphoma 43(8):1589-98, 2002. PMID: 11842389.
145. Tsimberidou AM, Thomas D, O'Brien S, Andreeff M, Kurzrock R, Keating M, Albitar M, Kantarjian H, Giles F. Recombinant human soluble tumor necrosis factor receptor fusion protein Enbrel in patients with refractory hematologic malignancies. Cancer Chemother Pharmacol 50(3):237-42, 2002. PMID: 12203106.
146. Tsimberidou AM, Sarris AH, Medeiros LJ, Mesina O, Rodriguez MA, Hagemeister FB, Romaguera J, Pro B, McLaughlin P, Dang N, Cabanillas F. Hodgkin's disease in patients infected with human immunodeficiency virus: frequency, presentation and clinical outcome. Leuk Lymphoma 41:535-44, 2001. PMID: 11378571.
147. Sarris AH, Hagemeister F, Romaguera J, Rodriguez MA, McLaughlin P, Tsimberidou AM, Medeiros LJ, Samuels B, Pate O, Oholendt M, Kantarjian H, Burge C, Cabanillas F. Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial. Ann Oncol 11:69-72, 2000. PMID: 10690390.
148. Tsimberidou AM, Yataganas X. Mechanisms of multiple drug resistance (MDR) in hematologic malignancies and solid tumors. Iatriki 78:413-24, 2000.
149. Meletis J, Tsimberidou A, Tsironi M, Stratigaki M, Meletis C, Samarkos M, Terpos E, Poziopoulos C, Konstantopoulos K, Loukopoulos D. Acute de novo basophilic leukemia presenting with skin involvement and upper gastrointestinal tract ulcerations. Haema 1:100-4, 1998.
150. Meletis J, Terpos E, Tsimberidou A. Congenital dyserythropoietic anemia type II (HEMPAS). Archives of Hellenic Medicine 15:215, 1998.
151. Michali E, Terpos E, Samarkos M, Meletis C, Tsimberidou A, Nodaros K, Vavourakis E, Konstantopoulos K, Kanellopoulou G, Variami E, Loukopoulos D, Meletis J. Detection of PNH red cell populations in hematologic disorders. Hippocrates 6:21-7, 1998.
152. Meletis J, Terpos E, Tsimberidou A. Flashes in clinical haematology. Case 2. Haema 1:107, 1998.
153. Meletis J, Samarkos M, Mesogitis S, Meletis C, Mougiou A, Terpos E, Tsimberidou A, Andreopoulos A, Konstantopoulos K, Loukopoulos D. Severe aplastic anemia relapsing during a pregnancy, spontaneous remission following termination. Haematologia 29:147-51, 1998. PMID: 9728807.
154. Meletis J, Michali E, Samarkos M, Konstantopoulos K, Meletis C, Terpos E, Tsimberidou A, Chandrinou E, Viniou N, Rombos Y, Pangalis GA, Yataganas X, Loukopoulos D. Detection of PNH red cell populations in hematological disorders using the Sephacryl Gel Test micro typing system. Leuk Lymphoma 28:177-82, 1997. PMID: 9498717.
155. Meletis J, Terpos E, Tsimberidou A. Disseminated candida albicans infection in a patient with hereditary myeloperoxidase deficiency. Archives of Hellenic Medicine 14:338, 1997.

Invited Articles

1. Said R, Tsimberidou AM. Pharmacokinetic evaluation of vincristine for the treatment of lymphoid malignancies. Expert Opin Drug Metab Toxicol. e-Pub 2/2014. PMID: 24512004.
2. Tsimberidou AM, Eggermont AM, Schilsky RL. Precision cancer medicine: The future is now, only better. American Society Clinical Oncology Educational Book 34:61-9, 2014. PMID: 24857061.
3. Tsimberidou AM, Ringborg U, Schilsky RL. Strategies to overcome clinical, regulatory, and financial challenges in the implementation of personalized medicine. American Society Clinical Oncology Educational Book:118-25, 2013. PMID: 23714475.
4. Tsimberidou AM, Chandhasin C, Kurzrock R. Farnesyltransferase Inhibitors: Where are we now? Expert Opin Investig Drugs 19(12):1569-80, 12/2010. e-Pub 11/2010. PMID: 21083522.
5. Tsimberidou AM. Ofatumumab in the treatment of chronic lymphocytic leukemia. Drugs of Today - Prous Thomson Reuters 46(7):451-61, 7/2010. PMID: 20683500.
6. Bustinza E, Kurzrock R, Tsimberidou AM. Salirasib in the treatment of pancreatic cancer. Future Oncology, (Cover Sidebar) 6(6):885-91, 6/2010.
7. Tsimberidou AM, Keating MJ. Other malignancies in chronic lymphocytic leukemia/small lymhocytic lymphoma: Analysis of 2028 patients. Am J Hematol Oncol 8(9):430-2, 9/2009.
8. Aguilera D, Tsimberidou AM. A review of dasatinib in the treatment of chronic myelogenous leukemia. Ther Clin Risk Manag 5:281-9, 2009.
9. Tsimberidou AM, Keating MJ, Wierda WG. Richter transformation in chronic lymphocytic leukemia. Curr Hematol Malig Rep 2(4):265-71, 2007.
10. Tsimberidou AM, Estey E. Treatment of older patients with acute myeloid leukemia. Aging Health 3(5):663-73, 2007.
11. Tsimberidou AM, Kantarjian H, Keating MJ, Estey E. Optimizing treatment for elderly patients with acute promyelocytic leukemia - Is it time to replace chemotherapy with all-trans retinoic acid and arsenic trioxide. Leuk Lymphoma 47(11):2282-8, 2006.
12. Tsimberidou AM, Khouri I, Keating MJ. Response, survival, failure-free survival, and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem cell transplantation. Am J Clin Oncol 5(1):662-5, 2006.
13. Tsimberidou AM, Keating MJ. Richter's transformation in chronic lymphocytic leukemia. Semin Oncol 33(2):250-6, 2006.
14. Tsimberidou AM, Keating MJ. Richter syndrome: biology, incidence, and therapeutic strategies. Cancer 103(2):216-28, 2005. PMID: 15578683.
15. Tsimberidou AM, Keating MJ. Richter's syndrome: Biology, incidence, and therapeutic strategies. Am J Clin Oncol Review 4:392-7, 2005.
16. Sarris AH, Jiang Y, Tsimberidou AM, Thomaides A, Rassidakis GZ, Ford RJ, Medeiros LJ, Cabanillas F, McLaughlin P. Quantitative real-time polymerase chain reaction for monitoring minimal residual disease in patients with advanced indolent lymphomas treated with rituximab, fludarabine, mitoxantrone, and dexamethasone. Semin Oncol 29(Suppl 2):48-55, 2002.
17. Tsimberidou AM, Alvarado Y, Giles FJ. The evolving role of ribonucleotide reductase inhibitors in hematologic malignancies. Expert Rev Anticancer Ther 2(4):437-48, 2002.
18. Tsimberidou AM. TNF-α targeted therapeutic approaches in patients with hematologic malignancies. Expert Rev Anticancer Ther 2(3):277-86, 2002.

Editorials

1. Tsimberidou AM, Minotti G, Cardinale D. Managing cardiac risk factors in oncology clinical trials. Tex Heart Inst J 38(3):266-7, 2011. PMCID: PMC3113125.
2. Tsimberidou AM, Estey EH. The significance of anemia in elderly patients with cancer. Oncology (Cover Sidebar) 21(1):100,104, 2007.
3. Tsimberidou AM, Estey E. Induction mortality risk in adult acute myeloid leukemia. Leuk Lymphoma 47(7):1199-1200, 2006.

Abstracts

1. Westin S, Sun C, Pal N, Janku F, Tsimberidou A, Falchook G, Hong D, Lu K, Coleman R, Kurzrock R. KRAS mutation in endometrial and ovarian cancers: Preliminary data on association with phenotype and clinical outcome in primary disease. Society of Gynecologic Oncology. In Press.
2. Tsimberidou AM, Ye Y, Adamopoulos AM, Piha-Paul S, fu S, Kurzrock R, Falchook G, Janku F, Fortier A, Hess KR, Wolff RA. Phase I clinical trial of bendamustine and bevacizumab for patients with advanced cancer. NCCN Conference 2013. In Press.
3. Ganesan P, Piha-Paul SA, Naing A, Falchook G, Wheler J, Fu S, Hong DS, Kurzrock R, Janku F, Laday S, Bedikian AY, Kies M, Wolff R, Tsimberidou AM. Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer. AACR 2013 Annual Meeting (#1178). In Press.
4. Bupathi M, Falchook GS, Hong DS, Subbiah IM, Piha-Paul SA, Karp DD, Saigal B, Zinner R, Wheler JJ, Tsimberidou AM, Fu S, Sherman SI, Meric-Bernstam F, Subbiah V. A phase 1 trial of vandetanib (multikinase inhibitor of EGFR, VEGFR, and RET) in combination with everolimus (mTOR inhibitor) in patients with advanced malignancies. 2014 ASCo Annual Meeting 32(5s) (#TPS2639), 5/2014.
5. Hou MM, Bellido J, Naing A, Falchook GS, Hess KR, Zinner R, Wheler JJ, Subbiah V, Hong DS, Piha-Paul SA, TsimberidouAM, Karp DD, Kurzrock R, Meric-Bernstam F, Fu S. A phase I trial of pazopanib and vorinostat: The role of TP53 mutations. 2014 ASCO Annual Meeting 32(5s) (#2576), 5/2014.
6. Legendre BL, Richardson K, Falchook GS, Naing A, Holley VR, Fu S, Hong DS, Piha-Paul SA, Wheler JJ, Zinner R, Subbiah V, Tsimberidou AM,Luthra R,Meric-Bernstam F, Bedikian AY, Eng C, Melnikova V, Lewis M, Kurzrock R, Janku F. BRAF and KRAS mutation testing in plasma cell-free DNA with ICE COLD-PCR in patients with advanced cancers. 2014 ASCO Annual Meeting 32 (#e22147), 5/2014.
7. Huang HJ, Claes B, Falchook GS, Naing A, Piha-Paul SA, Tsimberidou AM, Zinner R, Karp DD, Fu S, Subbiah V, Hong DS, Wheler JJ, Luthra R, Kee BK, Overman MJ, Kim K, Maertens GG, Kurzrock R, Meric-Bernstam F, Janku F. BRAF mutation testing in cell-free DNA from plasma of patients with advanced cancers using a novel, rapid, automated molecular diagnostics platform (Idylla). 2014 ASCO Annual Meeting 32 (#e22139), 5/2014.
8. Livingston JA, Hess KR, Fernandez JG, Naing A, Hong DS, Patel S , Anderson PM, Benjamin RS, Ludwig JA, Herzog CE, Fu S, Wheler JJ, Falchook GS, Tsimberidou AM, Piha-Paul SA, Janku F, Rohren E, Meric-Bernstam F, Kurzrock R, Subbiah V. Eliciting early-response signals from first-in-human clinical trials and validation of prognostic scores in aggressive biology bone cancers: The MD Anderson experience. 2014 ASCO Annual Meeting 32(5s) (#10531), 5/2014.
9. Tsimberidou AM, Ye Y, Wheler JJ, Falchook GS, Hong DS, Naing A,Fu S, Kurzrock R, Piha-Paul SA, Janku F, Zinner R, Moulder SL, Subbiah V, Karp DD, Meric-Bernstam F, Hwu P, Kies MS, Miller VA, Broaddus R, Hess KR. Genomic profiling and precision medicine in 3,745 patients with advanced cancer. 2014 ASCO Annual Meeting 32 (#e13521), 5/2014.
10. Subbiah IM, Varadhachary GR, Tsimberidou AM, Wheler JJ, Subbiah V, Falchook GS, Janku F, Zinner R, Roy-Chowdhuri S, Meric-Bernstam F, Hong DS. Next-generation sequencing in carcinoma of unknown primary (CUP) and novel combinatorial strategies in a heterogeneous mutational landscape: Implications for personalized medicine. 2014 ASCO Annual Meeting 32 (#e22154), 5/2014.
11. Subbiah V, Corrales-Medina FF, Herzog CE, Hess KR, Egas Bejar DE, Hong DS, Falchook GS, Anderson PM, Nunez C, Huh WW, Naing A, Tsimberidou AM, Wheler JJ, Piha-Pau SA, Janku F, Kleinerman E, Kurzrock R. Outcomes of pediatric cancer patients enrolled in phase 1 clinical trials designed for adults: Experience from a major cancer center. 2014 ASCO Annual Meeting 32 (#e21024), 5/2014.
12. Wheler JJ, Janku F, Atkins JT, Moulder SL, Zinner R, Lee JJ, Falchook GS, Tsimberidou AM, Piha-Paul SA, Harp DD, Naing A, Fu S, Hong DS, Subbiah V, Stephens PJ, Yelensky R, Miller VA, Valero V, Kurzrock R, Meric-Bernstam F. PI3K/AKT/mTOR genomic alterations in 94 patients with metastatic breast cancer in the phase I clinic at MD Anderson: Prevalence and association with response. 2014 ASCO Annual Meeting 32(5s) (#2606), 5/2014.
13. Liu X, George GC, Tsimberidou AM, Naing A, Wheler JJ, Kopetz S, Fu S, Piha-Paul SA, Eng C, Falchook GS, Janku F, Garrett CR, Karp DD, Kurzrock R, Zinner R, Singh Raghav KP, Subbiah V, Meric-Bernstam F,Hong DS, Overman MJ. Rechallenge with anti-EGFR–based therapy in metastatic colorectal cancer: Impact of intervening time interval and prior anti-EGFR response. 2014 ASCO Annual Meeting 32(5s) (#3607), 5/2014.
14. Fu S, Nguyen E, Janku F, Subbiah V, Patel SP, Falchook GS, Zinner R, Tsimberidou AM, Hong DS, Piha-Paul SA, Wheler JJ, Shi N, Bomalaski JS, Hwu P, Meric-Bernstam F. Targeting argininosuccinate synthetase-deficient advanced solid tumors in a phase I trial of ADI-PEG20 plus cisplatin. 2014 ASCO Annual Meeting 32(5s) (#2563), 5/2014.
15. Subbiah V, Agarwal R, Janku F, Tsimberidou AM, Patel S, Benjamin RS, Ludwig JA, Anderson PM, Araujo DM, Ravi V, Conley AP, Somaiah N, Wang WL, Naing A, Zinner R, Hong DS, Meric-Bernstam F. Diversity and heterogeneity in molecular analysis of advanced sarcomas: The clinical, regulatory, and financial challenge for drug development and precision medicine. 2014 ASCO Annual Meeting 32(5s) (#10595), 2014.
16. Huang M, Parkhurst KL, Jiang Y, Moulder SL, Naing A, Wheler JJ, Hong DS, Piha-Paul SA, Fu S, Tsimberidou AM, Zinner R, Janku F, Kurzrock R, Falchook GS. HER2 extracellular domain (ECD) and HER2 single nucleotide polymorphisms (SNPs) in patients treated with combination trastuzumab, lapatinib, and bevacizumab. 2014 ASCO Annual Meeting 32 (#e22082), 2014.
17. Ganesan P, Piha-Paul S, Naing A, Falchook G, Wheler J, Fu S, Hong DS, Kurzrock R, Jankui F, Laday S, Bedikian AU, Kies M, Wolff R, Tsimberidou AM. Phase I clinical trial of lenalidomide in combinatino with sorafenib in patients with advanced cancer. Cancer Res 73(8,Suppl 1) (#1178), 8/2013.
18. Tsimberidou AM, Hong DS, Wheler JJ, Ye Y, Fu S, Piha-Paul SA, Naing A, Falchook GS, Janku F, Aldape K, Wen S, Berry D, Kurzrock R. Personalized medicine for patients with advanced cancer in the Phase I program validation analysis. WIN 2013 Meeting Program, 7/2013.
19. Liu X, Hong DS, Fu S, Piha-Paul SA, McQuinn L, Falchook GS, Williams J, Karp D, Subbiah V, Tsimberidou AM, Janku F, Zinner R, Wheler JJ, Wolff RA, Kurzrock R, Naing A. Incidence of mucositis in patients treated with mTOR inhibitor-based regimens and correlation to treatment response. 2013 ASCO Annual Proceedings 31(15S) (#e13575), 6/2013.
20. Hou MM, Liu X, Wheler J, Naing A, Hong D, Bodurka D, Schmeler K, Tsimberidou AM, Janku F, Zinner R, Piha-Paul S, Lu K, Wolff R, Kurzrock R, Fu S. Outcome analyses of patients with metastatic cervical cancers in a phase I clinic. 2013 ASCO Annual Meeting 31(15S) (#e13534), 6/2013.
21. Tsimberidou AM, Said R, Falchook G, Janku F, Naing A, Zinner R, Blumenschein G, Fu S, Hong D, Piha-Paul S, Wheler J, Ye Y, Hes K, Palmer G, Wolff RA, Kurzrock R. Outcomes of patients with advanced cancer and KRAS mutation in phase I clinical trials. ASCO Annual Meeting Proceedings I 31(15S) (#e22086), www.asco.org and www.jco.org. e-Pub 6/2013.
22. Huang HJ, Devogelaere B, Falchook GS, Fu S, Angelo LS, Hong DS, Piha-Paul SA, Naing A, Holley VR, Tsimberidou AM, Stepanek VM, Kim KB, Subbiah V, Wheler JJ, Zinner RG, Wolff RA, Sablon E, Maertens G, Kurzrock R, Janku F. BRAF mutation testing with a novel, rapid, fully-automated molecular diagnostics prototype platform. 2013 ASCO Annual Meeting Proceedings 31(15S):677s (#11086), 5/2013.
23. Said R, Ye Y, Hong DS, Janku F, Fu S, Naing A, Wheler JJ, Kurzrock R, Palmer GA, Hess KR, Wolff RA, Thomas C, Tsimberidou AM. Characteristics and survival of patients with advanced cancer and TP53 mutations in phase I clinical trials. 2013 ASCO Annual Meeting Proceedings 31(15S):152s (#2545), 5/2013.
24. Wheler JJ, Yelensky, Moulder SL, Tsimberidou AM, Falchook GS, Janku F, Atkins JT, Zinner R, Karp DD, Hong DS, Stephens P, Wolff RA, Kurzrock R. Next generation sequencing (NGS) in patients with advanced metastatic breast cancer: identification of molecular alterations and analysis of associations with treatment on phase I studies at MD Anderson Cancer Center. 2013 ASCO Annual Meeting Proceedings 31(15S Supplement):61s (#1051), 5/2013.
25. Subbiah IM, Wheler J, Hess KR, Hong DS, Fu S, Kurzrock R, Wolff RA, Tsimberidou AM. Outcomes of patients ≥65 years with advanced cancer treated on phase clinical trials. 2013 ASCO Annual Meeting Proceedings 31(15S):586s (#9544), 5/2013.
26. Ganesan P, Piha-Paul SA, Naing A, Falchook GS, Wheler JJ, Janku F, Zinner R, Laday S, Kies MS, Tsimberidou AM. Phase I clinical trial of lenalidomide with temsirolimus in patients with advanced cancer. 2013 ASCO Annual Meeting Proceedings 31(15S):166s (#2604), 5/2013.
27. Prasanth G, Piha-Paul SA, Naing A, Falchook GS, Wheler JJ, Janku F, Zinner R, Laday S, Kies MS, Tsimberidou AM,. Phase I clinical trial of lenalidomide with temsirolimus in patients with advanced cancer. 2013 ASCO Annual Meeting Proceedings 31(15S) (#2604), 5/2013.
28. Westin SN, Smart ML, Pal N, Urbauer DL, Janku F, Wheler JJ, Piha-Paul SA, Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Zinner R, Subbiah V, Culotta KS, Lu KH, Coleman RL, Kurzrock R. Phase I trial of sorafenib, bevacizumab, and temsirolimus in advanced solid tumors. 2013 ASCO Annual Meeting Proceedings 31(15S):168s (#2611), 5/2013.
29. Wheler JJ, Moulder SL, Naing A, Janku F, Piha-Paul SA, Falchook GS, Zinner R, Tsimberidou AM, Fu S, Hong DS, Atkins JT, Cronin M, Yelensky R, Stephens P. A dose-escalation study of anastrozole and everolimus in patients with advanced gynecologic and breast malignancies: tolerance, biological activity, and molecular alterations in the P13K/AKT/mTOR pathway. Cancer Res 73(8, Suppl 1) (#3514), http://doi: 10.1158/1538-7445.AM2013-3514, 4/2013.
30. Janku F, Angelo LS, Devogelaere B, Falchook GS, Fu S, Huang HJ, Tsimberidou AM, Hong DS, Stepanek VM, Holley VR, Routbort MJ, Luthra R, Sablon E, Maertens G, Kurzrock R. BRAF mutation testing with a novel rapid fully automated biocartis moecular diagnostics protype platform. Cancer Res 73(8, suppl 1) (#4126), http://doi: 10.1158/1538-7445.AM2013-4126, 4/2013.
31. Chae YK, Kim K, Hong DS, Falchook GS, Piha-Paul SA, Wheler JJ, Naing A, Fu S, Tsimberidou AM, Zinner RG, Subbiah V, Stepanek VM, Wolff RA, Kuirzrock R, Janku F. PIK3CA mutation, aspirin use and mortality in patients with metastatic colorectal cancer participating in early-phase clinical trials. Cancer Res 73(8, Suppl 1) (#164), http://doi: 10.1158/1538-7445.AM2013-164, 4/2013.
32. Subbiah IM, Janku F, Tsmberidou AM, Naing A, Kaseb AO, Hong DS, Subbiah V, Hess KR, Akmal O, Falchook GS, Kurzrock R. Characteristics and outcomes of patients with advanced hepatocellular carcinoma treate on phase I trials. J Clin Oncol 31(No 4 Suppl), 2/2013.
33. Tsimberidou AM, Ringborg U, Schilsky RL. Strategies to overcome clinical, regulatory, and financial challenges in the implementation of personalized medicine. AM Soc Clin Oncol Educ Book 2013:118-125, 2013. PMID: 23714475.
34. Subbiah IM, subbiah V, Kaseb AO, Janku F, Wheler JJ, Naing A, Fu S, Piha-paul SA, Hong DS, Falchook GS, Tsimberidou AM, Kurzrock R. Characteristics and outcomes of patients with gallbladder cancer and cholangiocarcinoma referred to a phase I clinic. J Clin Oncol 30, 2012(30):(suppl 4; abstr 364), 11/2012.
35. Amin HM, Falchook GS, Fu S, Hong DS, Tsimberidou AM, Naing, A, Wheler JJ, Piha-Paul SA, Janku J, Klevesath MB, Jego V, Johne A, Kurzrock R. First-in-human phase I dose-escalation study of Ethe oral selective C-Met inhibitor EMD 1204831, in patients with advanced solid tumors. J Clin Oncol, 2012 ASCO Annual Meeting Proceedings 30(15 Suppl) (#3107), 10/2012.
36. Rodrigues HV, Parsons HA, Janku F, Naing A, Wheler JJ, Tsimberidou AM, Kurzrock R. A pilot study of temsirolimus and body composition. J Clin Oncol 30(15S) (#e13534), 5/2012.
37. Subbiah IM, Tsimberidou AM, Naing A, Subbiah V, Kaseb AO, Fu S, Hong DS, Piha-Paul SA, Wheler JJ, Janku F, Hess KR, Falchook GS, Kurzrock R. Early-phase trials compared to first-and second-line FDA-approved treatments in patients with advanced gallbladder cancer and cholangiocarcinoma. J Clin Oncol 30(15S) (#e13020), 5/2012.
38. Amin HM, Falchook GS, Fu S, Hong DS, Tsimberidou AM, Naing A, Wheler JJ, Piha-Paul SA, Janku F, Klevesath MB, Jego V, Johne A, Kurzrock R. First-in-human phase I dose escalation study of the oral selective C-met inhibitor EMD 1204831 inpatients with advanced solid tumors. J Clin Oncol 30(15S) (#3107^), 5/2012.
39. Madhusudanannair V, Janku F, Falchook GS, hong DS, Wheler JJ, Naing A, Fu S, Piha-Paul S, El-Osta HE, Luthra R, Tsimberidou AM, Kurzrock R. NRAS mutations in patients with advanced cancers treated with targeted therapies in early-phase clinical trials. J Clin Oncol 30(15S) (#3106), 5/2012.
40. Said R, Hong DS, Wheler JJ, Naing A, Falchook GS, Fu S, Janku F, Zinner R, Piha-Paul SA, Warneke CL, Tsimberidou AM, Kurzrock R. p53 mutations in advanced cancers: Clinical characteristics and outcomes in a phase I setting. J Clin Oncol 30(15S) (#10607), 5/2012.
41. Janku F, Broaddus R, Bakkar R, Hong DS, Stepanek VMT, Naing, Falchook GS, Fu S, Wheler JJ, Piha-Paul SA, Moulder SL, Luthra R, Tsimberidou AM, Kurzrock R. PTEN assessment and P13K/mTOR inhibitors: Importance of simultaneous assessment of MAPK pathway aberrations. J Clin Oncol 30(15S) (#10510), 5/2012.
42. Henary HA, Hong DS, Falchook GS, Tsimberidou AM, George G, Wheler JJ, Fu S, Naing A, Piha-Paul SA, Janku F, Kim KB, Hwu P, Kurzrock R. Targeted agents matached with tumor molecular aberrations: Review of 160 patients with advanced melanom treated in a phase I clinic. J Clin Oncol 30(15S) (#8551), 5/2012.
43. Subbiah IM, Kurzrock R, Naing A, Piha-Paul S, Falchook GS, Hong DS, Wheler JJ, Fu S, Tsimberidou AM. A phase I study of lenalidomide in combination with bevacizumab, sorafenib, temsirolimus, or 5-fluoracil, leucovorin, oxaliplatin (FOLFOX) in patients with advanced cancers. Cancer Res 72(8, Suppl 1) (#1751), doi: 10.1158/1538-7445.AM2012-1751. e-Pub 4/2012.
44. Subbiah IM, Tsimberidou AM, Naing A, Subbiah V, Kaseb A, Falchook GS, Fu S, Hong, D, Piha-Paul SA, Wheler JJ, Janku F, Kurzrock R. Early-phase trials in patients with advanced gallbladder cancer and cholangiocarcinoma: the MD Anderson Clinical Center for Targeted Therapy experience. Cancer Res 72(8,suppl 1) (#2669), http://doi: 10.1158/1538-7445.AM2012-2669, 4/2012.
45. Gonzalez-Angulo AM, Krop I, Piha-Paul S, Li Y, Culotta KS, Moulder-Thompson S, Tsimberidou AM, Velez-Bravo VM, Madden TL, Norberg LM, Doyle A, Winder EP, Mills GB, Meric-Bernstam F, Kurzrock R. Phase 1b dose escalation and biomarker study of MK2206 in combination with standard doses of weekly paclitaxel in patients with locally advanced or metastatic solid tumors with expansion in advanced breast cancer. 2012 AACR Annual Meeting:77, 3/2012.
46. Subbiah IM, Subbiah V, Kaseb AO, Janku F, Wheler JJ, Naing A, Fu S, Piha-Paul S, Hong D, Falchook G, Tsimberidou AM, Kurzrock R. Characteristics and outcomes of patients with gallbladder cancer and cholangiocarcinoma referred to a phase I clinic. J Clin Oncol, 2012 Gastrointestinal Cancers Symposium 31(4 suppl) (#364), 2/2012.
47. Naing A, Falchook S, Fu S, Amin HM, Piha-Paul SA, Hong DS, Tsimberidou AM, Wheler JJ, Janku F, Klevesath MB, Jego V, Johne A, Kurzrock R. A phase I dose-escalation study of EMD 1214063, an oral selective c-met inhibitor, in patients with advanced solid tumors. Ann Oncol - 10th Annual Meeting of JSMO 23(Suppl 11):xi21-xi23, 2012.
48. Tsimberidou AM, Hong DS, Wheler J, Ye Y, Fu S, Piha-Paul S, Naing A, Falchook G, Janku F, Luthra R, Wen S, Kurzrock R. Pesonalized medicine: an update on 1,985 patients with advanced cancer at MD Anderson Cancer Center. Ann Oncol, 4th WIN Symposium 23(Suppl 5):V10 (#L6.5), http://doi.1093/annonc.mds160, 2012.
49. Hong DS, Naing A, Falchook GS, Piha-Paul SA, Wheler JJ, Fu S, Tsimberidou AM , Hui D, Scott R, Khan R, Mistry R, Talley J, Chauhan S, Bermudez D, Stecher M, Simard J, Kurzrock R. A phase I study of MABp1, a first-in-human, first-true human monoclonal antibody against the IL-1 in patients with advanced cancers. Molecular Cancer Therapeutics 10(11):S1, 11/2011.
50. Hong DS, Naing A, Falchook GS, Piha-Paul S, Wheler JJ, Fu S, Tsimberidou AM, Hui D, Scott R, Khan R, Mistry R, Talley J, Bermudez D, Kumar S, Stecher M, Simard J, Kurzrock R. A phase I study of MABp1, a first-in-human use of a true human, monoclonal antibody against IL-1a in patients with advanced cancers. Mol Cancer Ther 10(11, Suppl 1) (#A211), 11/2011.
51. Janku F, Naing A, Stepanek VT, Falchook GS, Hong DS, Tsimberidou AM, Fu S, Lee JJ, Luthra R, Wheler JJ, Kurzrock R. PIK3CA mutations H1047R are associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Molecular Cancer Therapeutics 10(11):S1, 11/2011.
52. Falchook GS, Fu S, Amin HM, Tsimberidou AM, Hong DS, Naing A, Klevesath MB, Mattiacci MR, Johne A, Kurzrock R. Phase I dose-escalation study of the oral selective c-met inhibitor EMD 1204831 in patients with advanced solid tumors. European Journal of Cancer ECCO-ESMO 47(Supplement 1):S158 (#1245), 9/2011.
53. Tsimberidou AM, Wierda W, Wen S, Plunkett W, O'Brien S, Kipps T, Jones J, Kantarjian H, Keating MJ. Final results of a phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab (OFAR) combination therapy in patients with aggressive, relapsed/refractory chronic lymphocytic leukemia (CLL) and richter syndrome (RS). Annals of Oncology 11th International Conference on Malignant Lymphoma 22(Supplement 4):iv119 (#112), 6/2011.
54. Tsimberidou AM, Iskander NG, Hong DS, Wheler JJ, Fu S, Piha-Paul SA, Naing A, Falchook GS, Janku F, Luthra R, Wen S, Kurzrock R. Personalized medicine in a phase I clinical trials program: The MD Anderson Cancer Center initiative. J Clin Oncol 29(15S):165S (#CRA2500), 6/2011.
55. Fok J, Kurzrock R, Tsimberidou AM, Wen S, Naing A, Hong DS, Janku F, Falchook GS, Piha-Paul SA, Katz R, Fu S, Moulder SL, Wheler JJ. An umbrella protocol for histology-independent, phase I modular study based on EGFR mutation status: using erlotinib alone or in combination with cetuximab, bortezomib, or dasatinib to overcome resistance. 2011 ASCO Annual Meeting Proceedings 29(15S):174s (#2536), 5/2011.
56. Sun M, Falchook GS, Wheler JJ, Hong DS, Piha-Paul SA, Tsimberidou AM, Naing A, Fu S, Moulder SL, Wen S, Mueller P, Kurzrock R. Association of VEGF single nucleotide polymorphisms (SNPs) with response and toxicity in patients treated with bevacizumab. 2011 ASCO Annual Meeting (#e-13560), 5/2011.
57. El-Osta HE, Falchook GS, Tsimberidou AM, Hong DS, Naing A, Kim KB, Wen S, Janku F, Kurzrock R. Clinical characteristics and outcomes of patients with BRAF-mutant advanced cancer in a phase I clinic: The MD Anderson Cancer Center experience. 2011 ASCO Annual Meeting Proceedings 29(15S):638s (#10535), 5/2011.
58. Henary HA, Kurzrock R, Falchook GS, Naing A, Moulder SL, Wheler JJ, Tsimberidou AM, Durand JB, Yang P, Johansen J, Newman R, Khan R, Patgel U, Hong DS. Final results of a first-in-human phase I trial of PBI-05204, an inhibitor of AKT, FGF-2, NF-kb and p70S6K in advanced cancer patients. 2011 ASCO Annual Meeting Proceedings 29(15S):199s (#3023), 5/2011.
59. Vining D, Tsimberidou AM, Wang J, Garg N. Multimedia structured reporting: a picture is worth a thousand words. American Journal of Roentgenology 196(5):Supplement A10-A13 (#028), 5/2011.
60. Iskander NG, Tsimberidou AM, Letourneau K, Wen S, Wheler JJ, Hong DS, Naing A, Kurzrock R. Phase I clinical trial outcomes in 93 patients with brain metastases: The MD Anderson Cancer Center experience. 2011 ASCO Annual Meeting Proceedings 29(15S) (#e16546), 5/2011.
61. Kurzrock R, Patnaik A, Rosenstein L, fu S, Papadopoulos KP, Smith DA, Gonzales T, Tsimberidou AM, Mays TA, Cox DS, Hong DS, DeMarini DJ, Le NT, Morris SR, Tolcher AW. Phase I dose escalation of the oral MEK 1/2 inhibitor GSK 1120212 (GSK212) dosed in combination with the oral AKT inhibitor GSK2141795 (GSK795). 2011 ASCO Annual Meeting Proceedings 29(15S):215s (#3085), 5/2011.
62. Wheler JJ, Janku F, Jackson T, Fu S, Sun M, Yang H, Naing A, Moulder SL, Tsimberidou AM, Hong DS, Falchook GS, Piha-Paul SA, Garcia-Manero G, Kurzrock R. Phase I study of anti-VEGF monoclonal antibody bevacizumab and HDAC inhibitor valproic acid in patients with advanced cancers. 2011 ASCO Annual Meeting Proceedings 29(15S):178s (#2554), 5/2011.
63. Janku F, Garrido-Laguna I, Wheler JJ, Hong DS, Naing A, Falchook GS, Fu S, Moulder SL, Luthra R, Lee JJ, Tsimberidou AM, Kurzrock R. Screening for PIK3CA mutations, PTEN loss and RAS/RAF mutations in early-phase protocols with PI3K/mTOR pathway inhibitors. 2011 ASCO Annual Meeting Proceedings 29(15S):631s (#10507), 5/2011.
64. Stephen B, Wheler JJ, Tsimberidou AM, Wen S, Naing A, Hong DS, Falchook GS, Piha-Paul SA, Fu S, Janku F, Moulder SL, Kurzrock R. Survival of 1,181 patients in a phase I clinic: The MD Anderson Cancer Center experience. 2011 ASCO Annual Meeting Proceedings 29(15S):172s (#2528), 5/2011.
65. Veasey Rodrigues V, Naing A, Hong DS, Falchook GS, Fu S, Wheler JJ, Tsimberidou AM, Moulder SL, Janku F, Wen S, Fessahaye SN, Golden EC, Westerhold DI, Ewer M, Kurzrock R. The role of the electrocardiogram in phase I drug development in patients with cancer: The MD Anderson Cancer Center experience with 8,966 ECGs. 2011 ASCO Annual Meeting Proceedings 29(15S):176s (#2545), 5/2011.
66. Tsimberidou AM, Hong D, Wheler JJ, FU S, Piha-Paul S, Naing A, Falchook G, Luthra R, Iskander NG, Wen S, Kurzrock R. Profile-related evidence to determine individualized cancer therapy (PREDICT): Preliminary results of the personalized phase I clinical trials program at MD Anderson Cancer Center. Cance Res 71(8 Suppl 1) (#1287), 4/2011.
67. Tsimberidou AM, Wierda WG, Wen S, Plunkett P, O'Brien S, Kipps TJ, Jones JA, Kantarjian HM, Keating MJ. Results of a phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab (OFAR) combination therapy In patients with aggressive, relapsed/refractory chronic lymphocytic leukemia (CLL) and Richter syndrome (RS). American Society of Hematology 116(21):408 (#31774), 11/2010.
68. Janku F, Tsimberidou AM, Garrido-laguna I, Hong DS, Naing A, Falchook GS, Fu S, Luthra R, Wang X, Kurzrock R. Screening for PIK3CA, RAS, and RAF mutations in trials with PI3K/AKT/MTOR signaling pathway inhibitors. European Journal of Cancer Supplements 8(7):83 (#253), 11/2010.
69. Tsimberidou AM, Vaklavas C, Wen S, Hong D, Wheler J, Ng CS, Naing A, Uehara C, Wolff R, Kurzrock R. Clinical outcomes and prognostic factors in 83 patients with pancreatic cancer treated in phase I clinical trials at M. D. Anderson Cancer Center. Proceedings of the 101st Annual Meeting of the American Association of Cancer Research 28(15s) (#e13101), 5/2010. e-Pub 5/2010.
70. Vaklavas C, Tsimberidou AM, Wen S, Fu S, Hong DS, Wheler J, Naing A, Uehara C, Wolff RA, Kurzrock R. Clinical outcomes and prognostic factors of hepatic arterial infusion (HAI) chemotherapy combination regimens in 202 patients with advanced cancer metastatic to the liver: The Phase I Program M. D. Anderson Cancer Center. Proceedings of the American Society of Clinical Oncology 28(15s) (#E13101), 2010.
71. Tsimberidou AM, Wierda WG, Badoux X, Wen S, Plunkett W, O'Brien Sm, Kipps TJ, Jones JA, Kantarjian H, Keating MJ. Evaluation of oxaliplatin, fludarabine, cytarabine, and rituximab (OFAR) combination therapy in aggressive chronic lymphocytic leukemia (CLL) and Richter Syndrome (RS). Proceedings of the American Society of Clinical Oncology 28(15s):492s (#6521), 2010.
72. Cabanillas ME, Kurzrock R, Sherman SI, Tsimberidou AM, Waguespack S, Naing A, Busaidy N, Gagel R, Wright JJ, Hong DS,. Phase I trial of combination sorafenib and tipifarnib: the experience in advanced differentiated thyroid cancer (DTC) and medullary thyroid cancer (MTC). Annual Proceedings of the Society of Clinical Oncology 28s(15s):442s (#5586), 2010.
73. Janku, F, Tsimberidou AM, Garrido-Laguna I, Hong DS, Naing A, Falchook GS, Wheler JJ, Fu S, Piha-Paul SA, Kurzrock R. PIK3CA, KRAS and BRAF mutations in patients with advanced cancers treated with PI3K/AKT/mTor axis inhibitors. J Clin Oncol, 2010 ASCO Annual Meeting Proceedings 28(15S):224S (#2583), 2010.
74. Stephen S, Naing A, Hong DS, Fu S, Wheler JJ, Moulder SL, Falchook GS, Tsimberidou AM, Piha-Paul SA, Kurzrock R. The use of complementary and alternative medicine in patients seen in phase I clinical trials program. Proceedings of the American Society of Clinical Oncology 28(15s):658s (#9091), 2010.
75. Wheler JJ, Tsimberidou AM, Wen S, Naing A, Hong DS, Falchook GS, Piha-Paul SA, Fu S, Moulder SL, Kurzrock R. Toxicity in 1181 patients with advanced solid tumors treated in phase I clinical trials of predominantly targeted agents: The M. D. Anderson Cancer Center Experience. Proceedings of the American Society of Clinical Oncology 28(15s):230s (#2604), 2010.
76. Wheler, J, Tsimberidou A, Moulder S, Cristofanilli M, Hong D, Naing A, Pathak R, Liu S, Kurzrock R. Clinical outcomes of patients with breast cancer in a phase I clinic: The M.D. Anderson Cancer Center experience. San Antonio Breast Cancer Symposium, 6/2009.
77. Wheler J, Tsimberidou A, Moulder S, Cristofanilli M, Hong D, Naing A, Pathak R, Liu S, Kurzrock R. Clinical outcomes of patients with breast cancer in a phase I clinic: The M. D. Anderson Cancer Center experience. Proceedings of the American Society of Clinical Oncology 27(15S Part I and II):54s (#1054), 5/2009.
78. Tsimberidou AM, Wierda WG, Plunkett WK, O'Brien S, Lerner S, Smith, SC, Kantarjian HM, Keating, MJ. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab in patients with Richter's syndrome, and relapsed or refractory B-cell chronic lymphocytic leukemia. Proceedings of the American Society of Clinical Oncology 27(15S Part of I of II):363s (#7031), 5/2009.
79. Tsimberidou AM, Hong D, Ng C, Wheler J, Naing A, Bedikian A, Eng C, Fortier A, Uehara C, Kurzrock R. A phase I study of hepatic arterial infusion of oxaliplatin in combination with systemic fluorouracil, leucovorin and bevacizumab in patients with advanced solid tumors metastatic to the liver. Procedings of the 100th Annual Meeting of the American Association for Cancer Research (#3596), 4/2009.
80. Tsimberidou AM, Akerley W, Ng C, Hong D, Uehara C, Warren T, Yu, MK, Swabb EA, Kurzrock, R. Azixa a microtubule formation inhibitor in solid tumors: Results of a Phase 1 clinical trial. Proceedings of the 100th Annual meeting of the American Association for Cancer Research (#3606), 4/2009.
81. Ewald BJ, Sampath D, Zevevic A, Tsimberidou AM, Wierda WG, Plunkett W. Fludarabine and ara-C increase oxaliplatin-induced DNA damage and cytoxicity in chronic lymphocytic leukemia. Proceedings of the 100th Annual Meeting of the American Association for Cancer Research (#5406), 4/2009.
82. Tsimberidou AM, Wierda W, Plunkett W, O'Brien S, Kipps TJ, Jones J, Smith S, Jalayer A, Kantarjian HM, Keating M. Oxaliplatin, fludarabine, cytarabine, and rituximab induces high response rates in aggressive chronic lymphocytic leukemia (CLL) and Richter's syndrome (RS). Blood (ASH Annual Meeting) 114(22):3443, 2009.
83. Ewald B, Sampath D, Zecevic A, Tsimberidou AM, Plunkett W, Wierda W. Fludarabine and Ara-C increase oxaliplatin-induced DNA damage and cytotoxicity in chronic lymphocytic leukemia. Leukemia 2008:38 (#35), 9/2008.
84. Zecevic A, Ewald B, Sampath D, Wierda W, Tsimberidou AM, Plunkett W. Oxaliplatin and Fludarabine treatment produces DNA double-strand breaks and activates DNA damage signaling in CLL. Leukemia 2008 (#25), 9/2008.
85. Tsimberidou AM, Wen S, O'Brien S , McLaughlin P , Wierda WG , Kantarjian H , Lerner S , Strom S , Freireich EJ, Medeiros L, Keating MJ. Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma: Analysis of 2028 patients. Annals of Oncology 19(Suppl 4) (#385), 6/2008.
86. Wheler JJ , Tsimberidou AM, Hong DS , Jackson TL, Polk DY , Pilat S, Liu S, Feng L, Kurzrock R. Survival of patients in a phase I clinic: The M.D. Anderson Cancer Center experience. Proceedings of the American Society of Clinical Oncology 27(15S Part I and II):162s (#3536), 6/2008.
87. Tsimberidou AM, Rudek M , Hong D. Ng C , Blair J , Goldsweig H , Kurzrock R. Phase 1 first-in-human study of s-trans, trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors. Proceedings of the American Society of Clinical Oncology 26(15S Part I and II):593s, 2008.
88. Tsimberidou AM, Hantarjian H, O'Brien S, Garcia-Manero G, Koller C, Jones D, Pierce S, Brandt M, Keating M, Estey E. All-trans retinoic acid and arsenic trioxide combination therapy induces high rates of durable molecular remission in newly diagnosed acute promyelocytic leukemia. Proceedings of the American Society of Hematology 110(11):543a (#1834), 11/2007.
89. Tsimberidou AM, Kantarjian H, Faderl S, Pierce S, Freireich E, Estey E. Exclusion of acute myeloid leukemia (AML) clinical trials of patients unlikely to respond. Proceedings of the American Society of Hematology 118(11):843a (#2867), 11/2007.
90. Tsimberidou AM, Estey E, Albitar M, Wen S, Brandt M, Pierce S, Kantarjian H, Kurzrock R,. Prognostic significance of tissue necrosis factor-alpha in newly diagnosed acute myeloid leukemia and high-risk myleodysplastic syndromes. Proceedings of the American Society of Hematology- Blood 110(11):133b (#4263), 11/2007.
91. Tam C, Keating M, Tsimberidou AM, O'Brien S, Ferrajoli A, Lerner S, Faderl S, Abruzzo L, Schlette E, Kantarjian H, Wierda W. The clinical usefulness of novel prognostic factors in CLL: A study of 477 patients with low-risk (non-11q non-17p) FISH and known IGVH mutation status. Proceedings of the American Society of Hematology-Blood 118:11 (#3079), 11/2007.
92. Tsimberidou AM, Tam C, Wierda WG, O'Brien S, Lerner S, Kantarjian HM, Keating MJ. The prognostic significance of 11q deletion detected by fluorescence in situ hybridization in untreated chronic lymphocytic leukemia. The M. D. Anderson Cancer experience. Blood 118(11):619a (#2078), 11/2007.
93. Tsimberidou AM, Kantarjian H, Faderl S, Pierce S, Freireich E, Estey E,. Untreated patients with acute myeloid leukemia, age 50-59 years and performance status 2 should be as eligible for targeted therapy as older patients. Proceedings of the American Society of Hematology-Blood 118(11):842a (#2864), 11/2007.
94. Tsimberidou AM, Tam C, Wierda W, O'Brien S, Lerner S, Keating M. Beta-2 microglobulin (β2M) is an independent prognostic factor for clinical outcomes in patients with CLL treated with frontline fludarabine, cyclophosphamide, and rituximab regardless of age, creatinine clearance or performance status. Proceedings of the American Society of Clinical Oncology 25(Suppl 18):364s (#7034), 2007.
95. Tsimberidou AM, Wierda W, O'Brien S, Wen S, Plunkett W, Kipps T, Lerner S, Kantarjian H, Freireich E, Keating M. Comparison of oxaliplatin, fludarabine, cytarabine, and rituximab therapy with cyclophosphamide, vincristine, liposomal daunorubicin, dexamethasone, rituximab and GM-CSF alternating with methotrexate, cytarabine, rituximab GM-CSF therapy: Analysis of 53 patients with Richter's syndrome. XII International Workshop on CLL, London, UK ( Supplement 1 to Leukemia and Lymphoma) 48:S170 (#P5.17), 2007.
96. Tsimberidou AM, Kantarjian HM, Wen S, Keating MJ, O'Brien S, Cortes J, Pierce S, Brandt M, Freireich E, Estey E. Prognostic score including serum β2 microglobulin levels to stratify patients with acute myeloid leukemia: analysis of 1,293 patients. European Hematology Association Conference, Vienna, Austria. The Hematology Journal 92(Suppl 1):22 (#59), 2007.
97. Tsimberidou AM, McLaughlin P, O'Brien S, Wen S, Wierda W, Manning J, Lerner S, Hess M, Kantarjian H, Freireich E, Keating MJ. A prognostic score for chronic lymphocytic leukemia and small lymphocytic lymphoma: analysis of 2189 patients. Proceedings of the American Society of Hematology 108(1):788a (#2783), 2006.
98. Tsimberidou AM, Kantarjian HM, Garcia-Manero G, Koller C, Jones DM, Keating MJ, Estey E. Clinical outcomes and rates of molecular remission with all-trans retinoic acid and arsenic trioxide combination therapy in newly diagnosed acute promyelocytic leukemia. Proceedings of the American Society of Clinical Oncology 24(Suppl 18):337s (#6503), 2006.
99. Tsimberidou AM, Werida W, O'Brien S, Plunkett W, Kipps T, Brown J, Lerner S, Kantarjian H, Keating MJ. Combination of oxaliplatin, fludarabine, cytarabine, and rituximab in patients with Richter's syndrome and fludarabine-refractory chronic lymphocytic leukemia. Proceedings of the American Society of Hematology 108(11):799a (#2825), 2006.
100. Tsimberidou AM. Genomic aberrations in chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute analysis of 1694 patients. Proceedings of the American Society of Hematology 108(11):327b (#4958), 2006.
101. Tsimberidou AM, Keating MJ, Kantarjian H, O'Brien S, Cortes J, Koller C, Pierce S, Brandt M, Beran M, Estey E. Granulocytic sarcoma is associated with event-free survival superior to that of acute myeloid leukemia. Proceedings of the American Society of Hematology 108(11):568a (#2008), 2006.
102. Garcia M, Deavers MT, Knoblock RJ, Chen W, Tsimberidou AM, Manning JM, Medeiros LJ. Myeloid sarcoma involving the gynecologic tract. A report of 11 cases and review of the literature. Proceedings of the United States and Canadian Academy of Pathology Annual Meeting, Atlanta, Georgia (#830), 2006.
103. Tsimberidou AM, O'Brien S, McLaughlin P, Wen S, Wierda W, Kantarjian H, Manning H, Lerner S, Hess M, Freireich EJ, Keating MJ. Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma: analysis of 2083 patients. Proceedings of the American Society of Hematology 108(11):790a (#2790), 2006.
104. Tsimberidou AM, Kantarjian HM, Keating MJ, O'Brien S, Wen S, Cortes J, Giles F, Koller CA, Garcia-Manero G, Pierce S, Brandt M, Freireich EJ, Estey EH. Prognostic significance of β-2 microglobulin levels in acute myeloid leukemia: analysis of 1,293 patients. Proceedings of the American Society of Hematology 108(11):240a (#802), 2006.
105. Tsimberidou AM, O'Brien S, Wierda WG, Garcia-Manero G, Lerner S, Keating MJ. A comparison of outcomes in patients with splenic marginal zone lymphoma or marginal zone leukemia/lymphoma treated with immunotherapy, chemoimmunotherapy, or chemotherapy. Ninth International Conference on Malignant Lymphoma, Lugano. Annals of Oncology 16(Suppl 5):v124 (#294), 2005.
106. Keating MJ, McLaughlin P, Tsimberidou AM, O'Brien S. Are chronic lymphocytic leukemia and small lymphocytic lymphoma the same disease?. IX International Conference on Malignant Lymhoma, Lugano, Switzerland 16(Suppl 5):v46 (#49), 2005.
107. Tsimberidou AM, O'Brien S, Khouri I, Giles F, Kantarjian H, Wen S, Smith S, Lerner S, Freireich E, Keating M. Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy and/or immunotherapy with or without stem cell transplantation. Blood 106(11):593a (#2097), 2005.
108. Tsimberidou AM, Keating M, McLaughlin P, O'Brien S, Wierda W, Ferrajoli A, Manning J, Kantarjian H. Comparison of small lymphocytic lymphoma with chronic lymphocytic leukemia. The M. D. Anderson Cancer Center experience. Blood 106(11):270a (#921), 2005.
109. Tsimberidou AM, O'Brien S, Wierda WG, Garcia-Manero G, Lerner S, Keating MJ. Effects of immunotherapy on survival and progression-free survival in patients with splenic marginal zone lymphoma or marginal zone leukemia/lymphoma. Proceedings of the American Society of Clinical Oncology 23:5805 (#6583), 2005.
110. Tsimberidou AM Keating M, Bueso-Ramos C, Kurzrock R. Epstein-Barr virus in patients with chronic lymphocytic leukemia. Blood 106(11):598a (#2113), 2005.
111. Tsimberidou AM. Outcome in patients with Richter's syndrome treated with chemotherapy and/or immunotherapy with or without stem cell transplantation. Third Annual Conference on Therapeutic Advances in the Treatment of Hematological Malignancies, Santa Monica, California, 2005.
112. Tsimberidou AM, Catovsky D, Schlette E, O'Brien S, Kantarjian H. Wierda W, Smith S, Wen S, Lerner S, Keating M. Outcomes in patients with splenic marginal zone lymphoma or marginal zone leukemia/lymphoma treated with immunotherapy, chemoimmunotherapy, or chemotherapy. Blood 106(11):270a (#922), 2005.
113. Tsimberidou AM, Catovsky D, Schlette E, O'Brien S, Wierda W, Garcia-Manero G, Lerner S, Keating MJ. Rituximab with or without chemotherapy is associated with prolonged survival in patients with splenic marginal zone lymphoma or marginal zone leukemia/lymphoma. XI International Workshop on CLL, New York, NY 46(Suppl 1):91 (#103), 2005.
114. Tsimberidou AM, O'Brien S, Kantarjian H, Koller C, Hagemeister F, Fayad L, Lerner S, Keating M. Transformation of chronic lymphocytic leukemia in Hodgkin's disease. The M. D. Anderson Cancer Center experience. Blood 106(11):287a (#976), 2005.
115. Kurzrock R, Khouri I, Bueso-Ramos C, Giles F, Pilat S, Thomas DA, Cortes J, Tsimberidou AM. Low-dose interleukin-11 has activity in patients with bone marrow failure. Proceedings of the American Society of Clinical Oncology 23:172 (#2538), 2004.
116. Tsimberidou AM, Tirado-Gomez M, Andreeff M, O'Brien S, Kantarjian HM, Keating MJ, Lopez-Berestein G, Estey E. Single agent liposomal-encapsulated (Lipo) all-trans retinoic acid (ATRA) can cure patients with untreated acute promyelocytic leukemia (APL): an update and comparison with an ATRA+idarubicin induction regimen. Proceedings of the American Society of Clinical Oncology 23:559 (#6513), 2004.
117. Tsimberidou AM, Giles FJ, Duvic M, Fayad L, Kurzrock R. Activity of interferon-alpha and isotretinoin in patients with advanced, refractory lymphoid malignancies. Blood 102(11):649a (#2400), 2003.
118. Giles F, Kantarjian H, Cortes J, Tsimberidou AM, Faderl S, Verstovsek S, Thomas D, Garcia-Manero G, Wierda W, Ferrajoli A, Kornblau S, Andreeff M, O'Brien S, Beran M, Estey E. Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with untreated acute myeloid leukemia or high-risk myelodysplastic syndromes. Blood 102(11):253b (#4740), 2003.
119. Alvarado Y, Kantarjian H, Cortes J, Verstovsek S, Faderl S, Garcia-Manero G, Tsimberidou A, Sznol M, Giles F. Phase I study of VNP4010M, a novel alkylating agent in patients with refractory hematologic malignancies. Proceedings of the American Society of Clinical Oncology 22:585 (#2351), 2003.
120. Giles FJ, List AF, Roboz GJ, Tsimberidou AM, Laurent D, Reitsma D, Kowalski M, Kantarjian H, Feldman EJ. Phase I/II study of PTK787/ZK222584 (PTK/ZK), a novel, oral VEGF-receptor inhibitor, in patients with myelofibrosis with myeloid metaphasia. Blood 102(11):922a (#3431), 2003.
121. Tsimberidou AM, Keating MJ, Giles F, Lerner S, Kantarjian H, O'Brien S. Phase II study of fludarabine and mitoxantrone in patients with chronic lymphocytic leukemia. Blood 102(11):358b (#5158), 2003.
122. Tsimberidou AM, Giles FJ, Duvic M, Fayad L, Kurzrock R. Phase II study of pentostatin in patients with T-cell lymphomas: update of an M. D. Anderson Cancer Center series. Blood 102(11):639a (#2360), 2003.
123. Kurzrock R, Tsimberidou AM, Giles FJ, Duvic M. Pilot study of recombinant human soluble tumor necrosis factor receptor (P75) fusion protein etanercept in patients with relapsed cutaneous T-cell lymphomas. Proceedings of the American Society of Clinical Oncology. 22:590 (#2374), 2003.
124. Tsimberidou AM, Estey E, Cortes J, Verstovsek S, Faderl S, Thomas D, Wierda W, Garcia Manero G, Kantarjian H, Giles FJ. Randomized comparison of idarubicin and cytarabine +/- interleukin in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndrome. Proceedings of the American Society of Clinical Oncology 22:585 (#2353), 2003.
125. Liu Q, Fayad L, Romaguera J, Hagemeister FB, Rodriguez MA, Younes A, Pro B, Verstovsek S, Cabanillas F, Tsimberidou A, Hess M, Ayala A, Clemons M, McLaughlin P. Stage IV indolent lymphoma: 25 years of treatment progress. Blood 102(11):398a (#1446), 2003.
126. Tsimberidou AM, Estey E, Cortes J, Thomas D, Garcia-Manero G, Faderl S, Verstovsek S, O'Brien S, Kantarjian H, Giles F. Adaptive randomization of idarubicin and Ara-C ± interleukin in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndrome. Blood 100(11):264b (#4585), 2002.
127. Giles FJ, Tsimberidou AM, Dabaja B, Kantarjian H, Keating M, O'Brien S. Alternating cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone / methotrexate, and ara-C with rituximab and GM-CSF in patients with relapsed / refractory chronic lymphocytic leukemia. Proceedings of the IX International Workshop on CLL, San Diego, California (#91), 2002.
128. Tsimberidou AM, Stavroyanni N, Viniou N, Tiniakou M, Papaioannou M, Marinakis T, Papadopoulos A, Papadaki HA, Megalakaki C, Sakellari I, Skandali A, Panagiotidis P, Matsouka P, Rombos Y, Yataganas X. Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral blood stem cell transplantation as post-remission treatment in patients with de novo acute myelogenous leukemia. Blood 100(11):861a (#3395), 2002.
129. Tsimberidou AM, McLaughlin P, Feng L, Ayala A, Younes A, Rodriguez MA, Romaguera J, Hagemeister FB, Smith TL, Cabanillas F. Duration of decreased absolute number of circulating CD4 cells and CD4/CD8 ratio in patients with indolent lymphoma treated with fludarabine. Blood 100(11):775a (#3064), 2002.
130. Tsimberidou AM, Estey E, Cortes J, Thomas D, Garcia-Manero G, Faderl S, Verstovsek S, O'Brien S, Kantarjian H, Giles F. Feasibility of Mylotarg, fludarabine, Ara-c and cyclosporine regimen as post-remission therapy in acute myelogenous leukemia. Blood 100(11):339a (#1315), 2002.
131. Tsimberidou AM, Waddelow T, Xiao QD, Albitar M, Giles FJ. Increase in plasma TNF-α levels during Enbrel treatment of patients with refractory multiple myeloma. Proceeding of American Society of Clinical Oncology:276a (#1101), 2002.
132. Tsimberidou AM, Estey E, Cortes J, Thomas D, Garcia-Manero G, Faderl S, Verstovesk S, O'Brien S, Kantarjian H, Giles H. Mylotarg, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33-positive primary resistant or relapsed acute myeloid leukemia. Blood 100(11):339a-340a (#1317), 2002.
133. Tsimberidou AM, Estey E, Cortes J, Thomas D, Garcia-Manero G, Faderl S, Verstovsek S, O'Brien S, Kantarjian H, Giles F. Mylotarg, fludarabine, cytarabine and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndrome. Blood 100(11):339a (#1316), 2002.
134. Apostolidou E, Cortes J, Tsimberidou AM, Estey E, Kantarjian H, Giles F. Mylotarg, liposomal daunorubicin, Ara-C and cyclosporine regimen in patients with relapsed/refractory acute myelogenous leukemia. Blood 100(11):268b (#4600), 2002.
135. Tsimberidou AM, Estey E, Cortes J, Thomas D, Garcia-Manero G, Faderl S, Verstovsek S, Beran M, Keating M, O'Brien S, Kantarjian H, Giles F. Nonleukemic granulocytic sarcoma in a single institution: frequency, presentation and clinical outcome. Blood 100(11):243b (#4494), 2002.
136. Tsimberidou AM, Tsionos K, Lee MS, Ford R, Lichtiger B, Luthra R, McLaughlin P, Medeiros LJ, Cabanillas F, Sarris AH. Quantitation of circulating cells bearing the t(14;18) in normal donors and patients with lymphoma. Proceedings of the American Society of Clinical Oncology:15a, 2000.

Book Chapters

1. Tsimberidou AM, Keating, MJ. Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL). In: 60 Years of Survival Outcomes at UTMDACC. Springer, 211-223, 2013.
2. Tsimberidou AM, Keating MJ. Targeted therapy in chronic lymphocytic leukemia. In: Targeted Cancer Therapy. Ed(s) Kurzrock R , Markman M. Humana Press: New York, 61-86, 2008.
3. Tsimberidou AM, Keating MJ. Hyperuricemic syndromes in cancer patients. In: Hyperuricemic Syndromes: Pathophysiology and Therapy. 147. Ed(s) Ronco C, Rodeghiero F. S. Karger, AG Basel, 47-60, 2005.
4. Tsimberidou AM, Jiang YF, Ford R, Cabanillas F, Sarris AH. Real-time polymerase chain reaction of genomic DNA for quantitation of t(14;18). In: Detection of minimal residual disease in hematologic malignancies by Zipf and Johnston. Ed(s) Zipf and Johnston. Humana Press: New York, 223-236, 2002.

Manuals, Teaching Aids, Other Teaching Publications

1. Tsimberidou AM. Rituximab. 4, 2nd. Ed(s) Schwab, M. The Encyclopedia of Cancer: Berlin, Heidelberg, 2642-2644, 2009.
2. Tsimberidou AM, Giles FJ. Chronic myelogenous leukemia. American College of Physicians, 2003.

Last updated: 9/12/2014